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ABC Age, Biomarkers (GDF-15, cTnT-hs, and
haemoglobin), and Clinical history
(previous bleeding)
ACCA Acute Cardiovascular Care Association
ACCOAST A Comparison of Prasugrel at the Time of
Percutaneous Coronary Intervention Or
as Pretreatment At the Time of Diagnosis
in Patients with Non-ST-Elevation
Myocardial Infarction
ACS Acute coronary syndrome
ADP Adenosine 5’-diphosphate
AF Atrial fibrillation
ANTARCTIC Platelet Function Monitoring to Adjust
Antiplatelet Therapy in Elderly Patients
Stented for an Acute Coronary Syndrome
ARCTIC-Interruption Assessment by a Double Randomisation of a
Conventional Antiplatelet Strategy Versus a
Monitoring-Guided Strategy for Drug-
Eluting Stent Implantation and, of Treatment
Interruption Versus Continuation 1 Year
After Stenting-Interruption
ART Arterial Revascularisation Trial
ASA Acetylsalicylic acid
ATACAS Aspirin and Tranexamic Acid for
Coronary Artery Surgery
ATLANTIC Administration of Ticagrelor in the Cath
Lab or in the Ambulance for New ST
Elevation Myocardial Infarction to Open
the Coronary Artery
BARC Bleeding Academic Research Consortium
b.i.d Bis in die (twice a day)
BMS Bare-metal stent
CABG Coronary artery bypass graft surgery
CAD Coronary artery disease
CHADS2 Cardiac failure, Hypertension, Age,
Diabetes, Stroke (Doubled)
CHA2DS2-VASc Cardiac failure, Hypertension, Age >_ 75 (2
points), Diabetes, Stroke (2 points)–Vascular
disease, Age 65–74, Sex category
CHARISMA Clopidogrel for High Atherothrombotic
Risk and Ischemic Stabilization,
Management, and Avoidance
CI Confidence interval
COGENT Clopidogrel and the Optimization of
Gastrointestinal Events Trial
CORONARY CABG Off or On Pump Revascularization
Study
CPG Committee for Practice Guidelines
CrCl Creatinine clearance
CREDO Clopidogrel for the Reduction of Events
During Observation
CRUSADE Can Rapid risk stratification of Unstable
angina patients Suppress ADverse
outcomes with Early implementation of
the ACC/AHA Guidelines
CURE Clopidogrel in Unstable Angina to Prevent
Recurrent Events
CYP Cytochrome P450
DAPT Dual antiplatelet therapy
DES Drug-eluting stent
EACTS European Association for Cardio-Thoracic
Surgery
EAPC European Association of Preventive
Cardiology
EAPCI European Association of Percutaneous
Cardiovascular Interventions
ESC European Society of Cardiology
EXAMINATION Clinical Evaluation of the Xience-V stent
in Acute Myocardial INfArcTION
EXCELLENT Efficacy of Xience/Promus Versus Cypher
to Reduce Late Loss After Stenting
FDA Food and Drug Administration
GUSTO Global Use of Strategies to Open
Occluded Coronary Arteries
HAS-BLED Hypertension, Abnormal renal and liver
function, Stroke, Bleeding history or
predisposition, Labile INR, Elderly
(> 65 years), Drugs and alcohol
HR Hazard ratio
I-LOVE-IT 2 Evaluate Safety and Effectiveness of the
Tivoli DES and the Firebird DES for
Treatment of Coronary Revascularization
INR International normalized ratio
ISAR Intracoronary Stenting and
Antithrombotic Regimen
ISAR-SAFE Intracoronary Stenting and
Antithrombotic Regimen: Safety and
Efficacy of 6 Months Dual Antiplatelet
Therapy After Drug-Eluting Stenting
ISAR-TRIPLE Intracoronary Stenting and
Antithrombotic Regimen–Testing of a 6-
Week Versus a 6-Month Clopidogrel
Treatment Regimen in Patients With
Concomitant Aspirin and Oral
Anticoagulant Therapy Following Drug-
Eluting Stenting
ITALIC Is There a Life for DES After
Discontinuation of Clopidogrel
IVUS XPL Impact of Intravascular Ultrasound
Guidance on Outcomes of XIENCE
PRIME Stents in Long Lesions
LATE Late coronary Arterial Thrombotic Events
LEAD Lower-extremities artery disease
LEADERS-FREE Prospective randomized comparison of
the BioFreedom biolimus A9 drug-coated
stent versus the gazelle bare-metal stent
in patients at high bleeding risk
LVEF Left ventricular ejection fraction
MACCE Major adverse cardiac and
cerebrovascular events
MACE Major adverse cardiovascular events
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..MATRIX Minimizing Adverse Haemorrhagic Events
by TRansradial Access Site and Systemic
Implementation of angioX
MI Myocardial infarction
NACE Net adverse clinical events
NCDR National Cardiovascular Data Registry
NNT Number needed to treat
NOAC Non-vitamin K oral anticoagulant
NORSTENT NORwegian coronary STENT trial
NSTE-ACS Non-ST elevation acute coronary syndrome
NSTEMI Non-ST-segment elevation myocardial
infarction
OAC Oral anticoagulant
o.d. Omni die (once a day)
OPTIMIZE Optimized Duration of Clopidogrel
Therapy Following Treatment With the
Zotarolimus-Eluting Stent in Real-World
Clinical Practice
OR Odds ratio
PARIS Patterns of Nonadherence to Antiplatelet
Regimens in Stented Patients
PCI Percutaneous coronary intervention
PEGASUS-TIMI 54 Prevention of Cardiovascular Events in
Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a
Background of Aspirin–Thrombolysis in
Myocardial Infarction 54
PIONEER AF-PCI Rivaroxaban and a dose- adjusted oral
vitamin K antagonist treatment strategy in
subjects with atrial fibrillation who
undergo percutaneous coronary
intervention
PLATO PLATelet inhibition and patient Outcomes
PPI Proton pump inhibitor
PRECISE-DAPT PREdicting bleeding Complications In
patients undergoing Stent implantation
and subsEquent Dual Anti Platelet
Therapy
PRODIGY PROlonging Dual antiplatelet treatment
after Grading stent-induced intimal
hYperplasia study
PROTECT Patient-Related Outcomes With Endeavor
vs Cypher Stenting
q.d. Quaque die (one a day)
RCT Randomized controlled trial
REDUAL-PCI Evaluation of Dual Therapy With
Dabigatran vs. Triple Therapy With
Warfarin in Patients With AFib That
Undergo a PCI With Stenting
RESET Real Safety and Efficacy of 3-Month Dual
Antiplatelet Therapy Following Endeavor
Zotarolimus-Eluting Stent Implantation
ROOBY Veterans Affairs Randomized On/Off
Bypass trial
RR Relative risk
RRR Relative risk reduction
SECURITY Second Generation Drug-Eluting Stent
Implantation Followed by Six- Versus
Twelve-Month Dual Antiplatelet Therapy
STEMI ST-segment elevation myocardial
infarction
STREAM STrategic Reperfusion Early After
Myocardial Infarction
SYNTAX Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac
Surgery
TIA Transient ischaemic attack
TIMI Thrombolysis In Myocardial Infarction
TL-PAS Taxus Liberté Post Approval Study
TRA 2P-TIMI 50 Thrombin Receptor Antagonist in
Secondary Prevention of
Atherothrombotic Ischemic Events
TRACER Thrombin Receptor Antagonist for
Clinical Event Reduction in Acute
Coronary Syndrome
TRILOGY ACS Targeted Platelet Inhibition to Clarify the
Optimal Strategy to Medically Manage
Acute Coronary Syndromes
TRITON-TIMI 38 Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition
with Prasugrel–Thrombolysis in Myocardial
Infarction
TROPICAL-ACS Testing Responsiveness to Platelet
Inhibition on Chronic Antiplatelet
Treatment For Acute Coronary
Syndromes Trial
VA Veterans’ Administration
VKA Vitamin K antagonist
WOEST What is the Optimal antiplatElet and
anticoagulant therapy in patients with
OAC and coronary StenTing
ZES Zotarolimus-eluting stent
ZEUS Zotarolimus-eluting Endeavor sprint stent
in Uncertain DES Candidates
24/7 24 h a day, seven days a week
1. Preamble
Guidelines and Focused Updates written under the auspices of the
European Society of Cardiology’s (ESC) Committee for Practice
Guidelines (CPG) summarize and evaluate available evidence with
the aim of assisting health professionals in selecting the best manage-
ment strategies for an individual patient with a given condition. The
CPG Guidelines’ and Focused Updates’ recommendations should
facilitate decision making of health professionals in their daily practice.
However, the final decisions concerning an individual patient must be
made by the responsible health professional(s) in consultation with
the patient and caregiver as appropriate.
A great number of guidelines and focused updates have been
issued in recent years by the ESC and by the European
Association for Cardio-Thoracic Surgery (EACTS) as well as by
other societies and organizations. Because of the impact on
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clinical practice, quality criteria for the development of guidelines
have been established in order to make all decisions transparent
to the user. The recommendations for formulating and issuing
ESC Guidelines can be found on the ESC website (http://www.
escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/
Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines
represent the official position of the ESC on a given topic and
are regularly updated.
Members of this Task Force were selected by the ESC and EACTS
to represent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a com-
prehensive review of the published evidence for management of a
given condition according to ESC Committee for Practice Guidelines
(CPG) policy and approved by the EACTS. A critical evaluation of
diagnostic and therapeutic procedures was performed, including
assessment of the risk–benefit ratio. The level of evidence and the
strength of the recommendation of particular management options
were weighed and graded according to predefined scales, as outlined
in Tables 1 and 2.
The experts of the writing and reviewing panels provided declara-
tion of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of interest
that arise during the writing period were notified to the ESC and
updated. The Task Force received its entire financial support from
the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines and of its Focused Updates. The Committee is also
responsible for the endorsement process of these documents. These
CPG documents undergo extensive review by the CPG and external
experts, and in this case by EACTS-appointed experts. After appro-
priate revisions the CPG documents are approved by all the experts
involved in the Task Force. The finalized document is approved by
the CPG for publication in the European Heart Journal and in the
European Journal of Cardio-Thoracic Surgery. These CPG docu-
ments were developed after careful consideration of the scientific
and medical knowledge and the evidence available at the time of their
dating.
The task of developing this CPG Focused Update in collaboration
with EACTS also includes the creation of educational tools and
implementation programmes for the recommendations including
condensed pocket guideline versions, summary slides, and an elec-
tronic version for digital applications (smartphones, etc.) as well as
other educational tools depending on the topic. These versions are
abridged and thus, if needed, one should always refer to the full text
version, which is freely available via the ESC website and hosted on
the EHJ website. The National Societies of the ESC are encouraged
Table 1 Classes of recommendations
Table 2 Levels of evidence
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to endorse, translate and implement all ESC Guidelines.
Implementation programmes are needed because it has been shown
that the outcome of disease may be favourably influenced by the
thorough application of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines
and official focused updates, disseminating them and implementing
them into clinical practice.
Health professionals are encouraged to take the ESC CPG
Guidelines and Focused Updates developed in collaboration with
EACTS fully into account when exercising their clinical judgment, as
well as in the determination and the implementation of preventive,
diagnostic or therapeutic medical strategies. However, the CPG
documents do not override in any way whatsoever the individual
responsibility of health professionals to make appropriate and accu-
rate decisions in consideration of each patient’s health condition and
in consultation with that patient or the patient’s caregiver where
appropriate and/or necessary. It is also the health professional’s
responsibility to verify the rules and regulations applicable to drugs
and devices at the time of prescription.
2. Introduction
The estimated number of patients requiring dual antiplatelet therapy
(DAPT), consisting of the combination of aspirin and an oral inhibitor
of the platelet P2Y12 receptor for adenosine 5’-diphosphate (ADP), is
considerable and has increased over time in Europe. Based on popu-
lation estimates from 2015, in the region of 1 400 000 and 2 200 000
patients per year may have an indication for DAPT after coronary
intervention or myocardial infarction (MI), respectively.1
This year, 2017, is the 21st anniversary of the publication of the
first randomized clinical trial to establish the superiority of DAPT
over anticoagulant therapy among patients undergoing percutaneous
coronary intervention (PCI) (Figure 1).2 Based on over 35 random-
ized clinical trials, including more than 225 000 patients, DAPT is
among the most intensively investigated treatment options in the field
of cardiovascular medicine. Along with progressive refinement of
P2Y12 inhibition strategies—embracing firstly safer (from ticlopidine
to clopidogrel) and then more potent and predictable (from clopi-
dogrel to ticagrelor or prasugrel) drugs—research has concomitantly
focused on optimal treatment duration. The need to investigate lon-
ger DAPT regimens firstly arose from concerns over late and very
Figure 1 History of dual antiplatelet therapy (DAPT) in patients with coronary artery disease. The size of the circles denotes sample size. The col-
ours of perimeters identify the type of included patient populations within each study. The colours within each circle identify the antiplatelet agent(s)
investigated. Head-to-head studies comparing similar durations of two different antiplatelet strategies are shown with a vertical line, whereas those
investigating different treatment durations are shown with a horizontal line. Studies investigating different treatment strategies or regimens and not
treatment durations or type (e.g. pre-treatment in ACCOAST, tailored therapy in GRAVITAS, double dose of clopidogrel in CURRENT OASIS 7,
etc.) are represented with a single colour indicating the P2Y12 inhibitor, which was tested on top of aspirin.
pts = patients.
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late stent thrombosis occurring after first-generation drug-eluting
stent (DES) implantation.3 Yet, the advent of safer newer-generation
DESs and the results of the most recent randomized controlled trials
(RCTs) have established a major paradigm shift in the way DAPT
should be conceived and used in clinical practice. DAPT remains a
highly effective preventive treatment for stent thrombosis across the
board; however, the risks of late and (even more) very late stent
thrombosis have declined considerably since the advent of newer-
generation DESs. Hence, the risk of bleeding associated with DAPT
prolongation beyond 1 year does not seem to be justified by the small
absolute benefit observed in terms of very late stent thrombosis pre-
vention. On the other hand, there is emerging evidence that DAPT
reduces the long-term risk of non-stent-related MI as well as stroke.
Hence, after 21 years of research, DAPT has moved from a local (i.e.
stent-related) to a systemic treatment strategy (i.e. capable of pre-
venting thrombotic arterial vessel occlusion), conveying global
patient protection (Figure 1).
There is, however, confusion in the community around the optimal
type and duration of DAPT in patients with established coronary
artery disease (CAD), undergoing coronary revascularization or
not.4 This derives from apparently conflicting results arising from the
available studies and limited evidence on various patient subsets (e.g.
elderly patients, with comorbidities or at greater bleeding risk) in
whom the trade-off between the benefits and risks of DAPT may dif-
fer from those observed in more selected patient cohorts included in
trials. Therefore, the scope of this focused update is to address rec-
ommendations on DAPT in patients with CAD.
2.1 Short- and long-term outcomes after
percutaneous coronary intervention
See Web Addenda.
2.2 Risk of stent thrombosis in relation to
stent type
See Web Addenda.
2.3 Short- and long-term outcomes after
coronary artery bypass surgery
See Web Addenda.
2.4 Short- and long-term outcomes after
medically managed acute coronary
syndrome
See Web Addenda.
3. Efficacy and safety of dual
antiplatelet therapy and risk
stratification tools
Current evidence suggests that DAPT mitigates the risk of stent
thrombosis across the whole spectrum, from acute to very late
events. However, treatment with DAPT beyond 1 year after MI, or
after PCI, exerts the majority of its benefit by reducing the rate of
spontaneous MI, which is associated with mortality rates of 15%.5
Nonetheless, because continued antiplatelet therapy is also associ-
ated with increased bleeding risk, it is necessary to weigh this risk
against the potential benefit. Current evidence suggests that the risk
of bleeding in patients on DAPT is proportionally related to its dura-
tion both within and beyond 1 year of treatment duration. Since the
benefits of prolonged DAPT, especially for mortality endpoints,
appear highly dependent on prior cardiovascular history [such as
prior acute coronary syndrome (ACS)/MI vs. stable CAD], and pre-
diction models to estimate on-DAPT bleeding risk have been devel-
oped, an individualized approach based on ischaemic vs. bleeding risk
assessment is warranted.
3.1 Dual antiplatelet therapy for the
prevention of stent thrombosis
See Web Addenda.
3.2 Dual antiplatelet therapy for the
prevention of spontaneous myocardial
infarction
See Web Addenda.
3.3 Dual antiplatelet therapy and
mortality rate
See Web Addenda.
3.4 Safety of dual antiplatelet therapy
See Web Addenda.
3.5 Risk stratification tools for ischaemia
and bleeding risks
Given the trade-off between ischaemic vs. bleeding risks for any given
DAPT duration, the use of scores might prove useful to tailor DAPT
duration in order to maximize ischaemic protection and minimize
bleeding risks in the individual patient.6 Most of the frequently used
risk scores for assessing ischaemic events7–9 and major bleeds10–12
were originally developed and validated for the prediction of events
occurring mainly during hospital stay or early on thereafter.13,14 As a
result, the application of these risk scores to decide upon DAPT
duration remains problematic, as only limited data exist exploring
their value to guide DAPT duration.13 On the other hand, the use of
risk scores that were specifically designed to guide and inform deci-
sion making on DAPT duration should be prioritized over other avail-
able risk scores (Table 3).
The DAPT score was developed from 11 648 patients enrolled in
the DAPT trial and was initially validated in 8136 patients enrolled in
the Patient-Related Outcomes With Endeavor vs. Cypher Stenting
(PROTECT) trial.15 This prediction rule identified nine factors [age,
congestive heart failure/low left ventricular ejection fraction (LVEF),
vein graft stenting, MI at presentation, prior MI or PCI, diabetes, stent
diameter <3 mm, smoking, and paclitaxel-eluting stent] resulting in a
score ranging from -2 toþ 10. Within the DAPT trial, a high-risk
score (i.e. a score >_2) selected patients who showed a reduction in
MI/stent thrombosis and cardiovascular or cerebrovascular events
risk [number needed to treat (NNT) for benefit for ischaemic event
reduction = 34] after a prolonged, 30-month DAPT, with only a
modest increase in bleeding risk (NNT for harm = 272). In turn, a
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.low-risk score (<2) selected patients recruited in the DAPT trial who
did not derive any reduction of ischaemic events from prolonging
DAPT, with a significant increase in moderate/major bleeding (NNT
for harm = 64). As DAPT duration was not randomized in the
PROTECT trial, the value of the DAPT score in guiding the duration
of therapy has so far only been shown for patients recruited to the
DAPT trial. Additional validation of the DAPT score to guide DAPT
duration is needed, especially in the context of less well-selected
patients as compared to those recruited in the DAPT trial and under-
going treatment with new-generation DES only.
Two independent predictive scores for bleeding [age, body mass
index, smoking, anaemia, creatinine clearance (CrCl), and triple ther-
apy at discharge] and MI or stent thrombosis [diabetes mellitus, ACS,
smoking, CrCl, prior PCI, and prior coronary artery bypass graft sur-
gery (CABG)] have also been developed from the Patterns of
Nonadherence to Antiplatelet Regimens in Stented Patients (PARIS)
registry.16 PARIS was a prospective, multicentre, observational study
of patients undergoing PCI with stent implantation in the USA and
Europe, which was designed to examine the different modes of
DAPT cessation and to investigate the influence of these modes on
subsequent clinical adverse events.17 This registry study included
patients with an indication for oral anticoagulation. The value of the
PARIS bleeding and/or ischaemic risk scores to tailor DAPT duration
remains unclear, since therapy duration was not randomized in the
PARIS study and no study to date has applied the results of these
scores for DAPT type or duration guidance. A high ischaemic risk sta-
tus was observed in roughly 40% of high bleeding risk patients16 and
as many as 65.3% presented low ischaemic and bleeding risks.16
Therefore, it remains unclear how DAPT duration should be guided
by the simultaneous assessment of ischaemic and bleeding risk fea-
tures according to PARIS.
The PRECISE-DAPT (PREdicting bleeding Complications In
patients undergoing Stent implantation and subsEquent Dual Anti
Platelet Therapy) collaborative study included a total of 14 963
patients with CAD who underwent elective, urgent, or emergent PCI
and generated a five-item (age, CrCl, haemoglobin, white blood cell
count, and prior spontaneous bleeding) prediction algorithm for out-
of-hospital bleeding in patients treated with DAPT.18
The predictive performance of this novel score was assessed in the
derivation cohort and validated in 8595 and 6172 patients treated with
PCI from the PLATelet inhibition and patient Outcomes (PLATO) trial
and the Bern PCI registry,19,20 respectively. The PRECISE-DAPT score
showed improved integrated discrimination and reclassification per-
formance as compared to the PARIS bleeding score in both validation
cohorts.18 The usefulness of this score was also assessed within
patients randomized to different DAPT durations (n = 10 081) to iden-
tify the effect on bleeding and ischaemia of a long (12–24 months) or
short (3–6 months) treatment duration in relation to baseline bleeding
risk. It was observed that among patients deemed at high bleeding risk
based on PRECISE-DAPT (PRECISE-DAPT score >_25), prolonged
Table 3 Risk scores validated for dual antiplatelet therapy duration decision-making
CHF = congestive heart failure; CrCl = creatinine clearance; DAPT = dual antiplatelet therapy; Hb = haemoglobin; LVEF = left ventricular ejection fraction; MI = myocardial
infarction; PCI = percutaneous coronary intervention; PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual
Anti Platelet Therapy; WBC = white blood cell count.
aFor the PRECISE-DAPT score use the score nomogram: mark patient’s value for each of the five clinical variables of the score and draw a vertical line to the ‘Point’ axis to
determine the number of points obtained for each clinical variable. Then summate the points obtained for each clinical variable to the total score. A practical case example for
score calculation is provided in Web Figure 1 of the Web Addenda.
For the DAPT score summate positive points for each value and subtract values for age to the total score.
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DAPT was associated with no ischaemic benefit but a remarkable
bleeding burden leading to an NNT for harm of 38.18 On the other
hand, longer treatment in patients without high bleeding risk
(PRECISE-DAPT score <25) was associated with no increase in bleed-
ing and a significant reduction in the composite ischaemic endpoint of
MI, definite stent thrombosis, stroke, and target vessel revasculariza-
tion, with an NNT for benefit of 65.18 Selecting a shorter than 12-
month treatment duration in patients deemed at high bleeding risk
upfront may therefore prevent their exposure to an excessive bleeding
hazard. In turn, patients at non-high bleeding risk might receive a stand-
ard (i.e. 12 months) or prolonged (i.e. >12 months) course of treat-
ment if tolerated.
However, none of these risk prediction models have been pro-
spectively tested in the setting of RCTs. Therefore, their value in
improving patient outcomes remains unclear.
3.6 Type of P2Y12 inhibitor and timing of
initiation
Clopidogrel: Clopidogrel is associated with a better safety profile than
ticlopidine, mainly in terms of allergy, skin or gastrointestinal disor-
ders, and neutropenia, while it has a similar degree and consistency of
P2Y12 inhibition and bleeding risk.
21,22 The wide variability in the
pharmacodynamic response to ticlopidine and clopidogrel is linked
to several factors, including genotype polymorphisms.22 Clinical evi-
dence with respect to the optimal duration of clopidogrel therapy
after PCI is discussed elsewhere (Chapter 4).
Prasugrel: Prasugrel achieves a faster, greater, and more consistent
degree of P2Y12 inhibition as compared to clopidogrel. Prasugrel
requires two metabolic steps for formation of its active metabolite,
which is chemically similar to the active metabolite of clopidogrel.
The Trial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in
Myocardial Infarction (TRITON-TIMI 38) included P2Y12 inhibitor-
naı̈ve ACS patients in whom coronary anatomy was deemed suitable
for PCI, or patients with ST-segment elevation myocardial infarction
(STEMI) referred for primary PCI.23 Duration of DAPT was up to
15 months in both study arms. The composite primary endpoint (car-
diovascular death, non-fatal MI, or stroke) occurred in 9.3% of
prasugrel-treated patients vs. 11.2% of clopidogrel-treated patients
[hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.73–0.93; P =
0.002], mostly driven by a significant risk reduction for MI [from 9.2%
to 7.1%; relative risk reduction (RRR) 23.9%, 95% CI 12.7–33.7; P <
0.001).23 There was no difference in the rates of either non-fatal
stroke or cardiovascular death.
Prasugrel was associated with a significant increase in the rate of
non-CABG-related TIMI major bleeding (2.4% vs. 1.8%; HR 1.32, 95%
CI 1.03–1.68; P = 0.03). Life-threatening bleeding was significantly
increased under prasugrel compared with clopidogrel (1.4% vs. 0.9%;
HR 1.52, 95% CI 1.08–2.13; P = 0.01), as was fatal bleeding (0.4% vs.
0.1%, HR 4.19, 95% CI 1.58–11.11; P = 0.002). CABG-related bleed-
ing was also higher in prasugrel-treated patients (13.4% vs. 3.2%; HR
4.72, 95% CI 1.90–11.82; P < 0.001). There was evidence of net harm
with prasugrel in patients with a history of cerebrovascular events. In
addition, there was no apparent net clinical benefit in patients
>_75 years of age and in patients with low body weight (<60 kg).23
Prasugrel was not tested in medically managed ACS patients in the
setting of the TRITON-TIMI 38 study. In the Targeted Platelet
Inhibition to Clarify the Optimal Strategy to Medically Manage Acute
Coronary Syndromes (TRILOGY ACS) study, which exclusively
included medically managed ACS patients, the primary endpoint of
death from cardiovascular causes, MI, or stroke among patients
under the age of 75 years occurred in 13.9% of the prasugrel group
and 16.0% of the clopidogrel group (HR 0.91, 95% CI 0.79–1.05; P =
0.21), at a median follow-up of 17 months.24 Similar results were
observed in the overall population (i.e. also including elderly patients).
Hence, prasugrel is not indicated in medically managed ACS patients.
The TRITON-TIMI 38 study mandated the use of prasugrel or clo-
pidogrel after coronary angiography if an indication to proceed to
PCI was established. Pre-treatment was allowed only in STEMI
patients undergoing primary intervention (n = 2438).
For the comparison of prasugrel at the time of PCI, in the A
Comparison of Prasugrel at the Time of Percutaneous Coronary
Intervention Or as Pretreatment At the Time of Diagnosis in Patients
with Non-ST-Elevation Myocardial Infarction (ACCOAST), 4033
patients with non-STEMI (NSTEMI) who were scheduled to undergo
coronary angiography within 2–48 h after randomization were assigned
to receive prasugrel (a 30 mg loading dose) before angiography (pre-
treatment group) or placebo (control group).25 When PCI was indi-
cated, an additional 30 mg of prasugrel was given in the pre-treatment
group at the time of PCI and 60 mg of prasugrel was given in the control
group. The rate of the primary efficacy endpoint, a composite of death
from cardiovascular causes, MI, stroke, urgent revascularization, or gly-
coprotein IIb/IIIa inhibitor rescue therapy (glycoprotein IIb/IIIa bailout)
through day 7, did not differ significantly between the two groups (HR
with pre-treatment 1.02, 95% CI 0.84–1.25; P = 0.81).25 The rate of the
key safety endpoint of all TIMI major bleeding episodes, whether related
to CABG or not, through day 7 was increased with pre-treatment (HR
1.90, 95% CI 1.19–3.02; P = 0.006). The rates of TIMI major bleeding
and life-threatening bleeding not related to CABG were increased by a
factor of 3 and 6, respectively. Pre-treatment did not reduce the rate of
the primary outcome among patients undergoing PCI (69% of the
patients) but increased the rate of TIMI major bleeding at 7 days.25
Hence, prasugrel is not indicated in patients with ACS in whom cor-
onary anatomy is not known and an indication for PCI is not clearly
established, with the exception of STEMI patients scheduled to undergo
immediate coronary catheterization and PCI, if clinically indicated.
In the DAPT trial, 3461 patients (34.7% of the total trial population)
who were treated with prasugrel within the first 12 months after
Use of risk scores as guidance for the duration of dual
antiplatelet therapy
Recommendations Classa Levelb
The use of risk scores designed to evaluate
the benefits and risks of different DAPT
durationsc may be considered.15,18
IIb A
DAPT = dual antiplatelet therapy.
aClass of recommendation.
bLevel of evidence.
cThe DAPT and PRECISE-DAPT scores are those currently fulfilling these
requirements.
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intervention were randomly allocated to stop or continue the treat-
ment for an additional 18 months.26 The type of P2Y12 inhibitor or stent
type were not randomized for. However, the largest cohort of prasu-
grel-treated patients (n = 2191) was provided by the TAXUS Liberté
Post Approval Study (TL-PAS), which was a prospective, multicentre,
open-label study developed to review the clinical performance of the
Taxus Liberté paclitaxel-eluting stent in routine clinical practice in the
USA.27 Enrolled TL-PAS patients received open-label prasugrel plus
aspirin for 12 months after stent placement; enrolment was not
restricted to patients presenting with ACS (i.e. those with an approved
indication for prasugrel). Rates of death and stroke were similar
between groups, but MI was significantly reduced with prolonged prasu-
grel treatment (1.9% vs. 7.1%; HR 0.255; P < 0.001). The DAPT co-
primary endpoint, stent thrombosis, was also lower with longer therapy
(0.2% vs. 2.9%; HR 0.063; P < 0.001). The safety endpoint of GUSTO
(Global Use of Strategies to Open Occluded Coronary Arteries) mod-
erate or severe bleeding was numerically increased in the patients con-
tinuing prasugrel to 30 months, although the difference was not
statistically significant (2.4% vs. 1.7%; HR 1.438; P = 0.234).27 No sub-
group data have been provided among patients treated with prasugrel
with respect to indication for PCI (i.e. ACS vs. stable CAD) or type of
implanted stent (i.e. paclitaxel-eluting stent vs. other stent types).
Ticagrelor: Ticagrelor belongs to a novel chemical class, cyclopentyl
triazolopyrimidine, and is a direct oral, reversibly binding P2Y12 inhibi-
tor with a plasma half-life of 12 h. In the PLATO trial, ticagrelor
proved to be superior to clopidogrel in ACS patients, who were
allowed to be pre-treated with clopidogrel at hospital admission, irre-
spective of the final revascularization strategy (i.e. planned or not
planned invasive management).20 Patients with either moderate- to
high-risk non-ST elevation ACS (NSTE-ACS) (planned for either
conservative or invasive management) or STEMI planned for primary
PCI were randomized to either clopidogrel 75 mg daily, with a loading
dose of 300 mg, or ticagrelor 180 mg loading dose followed by 90 mg
twice daily.20 Patients undergoing PCI were allowed to receive an
additional blinded 300 mg loading dose of clopidogrel (total loading
dose 600 mg) or its placebo, and were also recommended to receive
an additional 90 mg of ticagrelor (or its placebo) if > 24 h after the ini-
tial loading dose. Treatment was continued for up to 12 months, with
a minimum intended treatment duration of 6 months and a median
duration of study drug exposure of 9 months.20
In the overall cohort, the primary composite efficacy endpoint
(death from vascular causes, MI, or stroke) was observed in 9.8% of
the patients in the ticagrelor group and in 11.7% of the patients in the
clopidogrel group (HR 0.84, 95% CI 0.77–0.92; P < 0.001).20
According to the pre-defined statistical analysis plan, death from vas-
cular causes was significantly reduced from 5.1% to 4.0% (HR 0.79,
95% CI 0.69–0.91; P = 0.001), and from MI from 6.9% to 5.8% (HR
0.84, 95% CI 0.75–0.95; P = 0.005). There was no significant difference
in the rates of stroke (1.3% vs. 1.5%; P = 0.22). The rate of definite
stent thrombosis was reduced from 1.9% to 1.3% (P < 0.01) and total
mortality from 5.9% to 4.5% (P < 0.001). Overall, there was no signifi-
cant difference in PLATO-defined major bleeding rates between the
clopidogrel and ticagrelor groups (11.2% vs. 11.6%, respectively; P =
0.43). Major bleeding unrelated to CABG was increased from 3.8% in
the clopidogrel group to 4.5% in the ticagrelor group (HR 1.19, 95%
CI 1.02–1.38; P = 0.03). Major bleeding related to CABG was similar
with ticagrelor and clopidogrel (7.4% vs. 7.9%, respectively; P = 0.32).
There was no difference in the overall rates of fatal haemorrhage
between the groups (0.3% in both groups). The superiority of ticagre-
lor over clopidogrel with respect to the primary study endpoint as
well as cardiovascular death or overall mortality was consistent across
management strategies, i.e. patients undergoing PCI, those medically
managed, and patients who underwent CABG.20
No dedicated study exists assessing the value of early (i.e. before
coronary angiography) vs. delayed (i.e. after coronary angiography)
ticagrelor administration in patients with NSTE-ACS. The
Administration of Ticagrelor in the Cath Lab or in the Ambulance for
New ST Elevation Myocardial Infarction to Open the Coronary Artery
(ATLANTIC) study involved 1862 patients with STEMI <6-h duration
and compared pre-hospital (in the ambulance) vs. in-hospital (in the
catheterization laboratory) treatment with ticagrelor.28 The co-
primary endpoints were the proportion of patients who did not have
>_70% resolution of ST-segment elevation before PCI and the propor-
tion of patients who did not have TIMI flow grade 3 in the infarct-
related artery at initial angiography. Secondary endpoints included the
rates of major adverse cardiovascular events (MACE) and definite
stent thrombosis at 30 days. The median time difference between the
two treatment strategies was 31 min. The two co-primary endpoints
did not differ significantly between the pre-hospital and in-hospital
groups. The rates of definite stent thrombosis were lower in the pre-
hospital group than in the in-hospital group (0% vs. 0.8%, P = 0.008 in
the first 24 h; 0.2% vs. 1.2%, P = 0.02 at 30 days). Rates of major bleed-
ing events were low and virtually identical in the two groups, regardless
of the bleeding definition used.28
The value of ticagrelor beyond 12 months of therapy in patients
with prior ACS has been investigated in the Prevention of
Cardiovascular Events in Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of
Aspirin–Thrombolysis in Myocardial Infarction (PEGASUS) trial,
which is described in Chapter 4.29
P2Y12 inhibitors in STEMI patients treated with lysis: Clopidogrel is the
only P2Y12 inhibitor that has been properly investigated in patients
with STEMI undergoing initial treatment with thrombolysis.31,32
Clopidogrel 300 mg loading dose has been investigated only in
patients <_75 years of age.31 While not specifically investigating the
value of clopidogrel, in the STrategic Reperfusion Early After
Myocardial Infarction (STREAM) study, patients aged 75 or more
received clopidogrel treatment without loading dose (i.e. initiated at
75 mg q.d.) in association with half dose of lytic therapy.30 Hence, the
administration of a clopidogrel loading dose in elderly patients
requires a patient-by-patient decision. While prasugrel33 or ticagre-
lor20 were allowed as per protocol in patients with prior treatment
with lysis in P2Y12 inhibitor-naı̈ve patients or those with prior clopi-
dogrel administration, respectively, there are insufficient safety data to
recommend their concomitant use during or soon after thrombolysis.
Timing of initiation of P2Y12 inhibitor: The evidence (and lack thereof)
on optimal timing for the initiation of P2Y12 inhibitors has been
extensively discussed in previous guidelines34 and reviewed else-
where.35,36 A reasonable approach is to start treatment with a P2Y12
inhibitor based on the timing with which the drug was investigated in
approval studies (i.e. start as soon as possible and deemed safe for
clopidogrel and ticagrelor or after the indication for PCI is established
based on coronary anatomy for prasugrel). The decision to withhold
early administration of P2Y12 inhibitors may also depend on planned
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.use of cangrelor in the catheterization laboratory, which ensures
immediate inhibition of the target receptor in oral P2Y12 inhibitor-
naı̈ve patients. Timing of administration of P2Y12 inhibitors in patients
receiving cangrelor infusion at the time of PCI should be drug-spe-
cific.37 While ticagrelor can be given any time before, during or at the
end of cangrelor infusion, it is recommended that clopidogrel or pra-
sugrel is given at the time of cangrelor infusion discontinuation (or
within 30 minutes before the end of infusion in the case of prasugrel
administration).37 However, the comparative efficacy and safety of
routine early oral P2Y12 inhibitor administration vs. the use of cangre-
lor in the catheterization laboratory in patients with ACS undergoing
invasive management deserves further investigation. If coronary anat-
omy is known or the probability of PCI is high (such as for STEMI
patients), there is evidence and general consensus that early adminis-
tration of oral P2Y12 inhibitors outweighs any potential risks. On the
other hand, there are no convincing data that the benefits of early
administration of a P2Y12 inhibitor outweigh the possible risks in sta-
ble CAD patients undergoing diagnostic angiography.
3.7 Measures to minimize bleeding while
on dual antiplatelet therapy
Bleeding events after successful PCI are independently associated
with increased mortality and morbidity and this association is likely
causal.41,42 Therefore, every effort should be made to minimize
bleeding. Individualization of therapy is a key measure and includes
the identification of risk factors for bleeding, radial access site, dosing
of therapies, use of proton pump inhibitors (PPIs), and appropriate
selection of P2Y12 inhibitors.
Vascular access site: The Minimizing Adverse Haemorrhagic Events
by Transradial Access Site and Systemic Implementation of angioX
(MATRIX) trial is the most contemporary and largest trial on access
site selection where 8404 ACS patients were randomly allocated to
radial or femoral access.43 The first co-primary outcome of 30-day
MACE—defined as death, MI, or stroke—occurred in 8.8% of patients
with radial access and 10.3% of patients with femoral access [relative
risk (RR) 0.85, 95% CI 0.74–0.99; two-sided P = 0.031; formally non-
significant at the pre-specified a of 0.025]. The second co-primary
Recommendations on P2Y12 inhibitor selection and timing
Recommendations Classa Levelb
In patients with ACS, ticagrelor (180 mg loading dose, 90 mg twice daily) on top of aspirinc is recommended, regardless
of initial treatment strategy, including patients pre-treated with clopidogrel (which should be discontinued when ticagre-
lor is commenced) unless there are contraindications.20
I B
In patients with ACS undergoing PCI, prasugrel (60 mg loading dose, 10 mg daily dose) on top of aspirin is recom-
mended for P2Y12 inhibitor-naı̈ve patients with NSTE-ACS or initially conservatively managed STEMI if indication for
PCI is established, or in STEMI patients undergoing immediate coronary catheterizationc unless there is a high risk of
life-threatening bleeding or other contraindications.23
I B
Pre-treatment with a P2Y12 inhibitor is generally recommended in patients in whom coronary anatomy is known and
the decision to proceed to PCI is made as well as in patients with STEMI.20,23,38
I A
In patients with NSTE-ACS undergoing invasive management, ticagrelor administration (180 mg loading dose, 90 mg
twice daily), or clopidogrel (600 mg loading dose, 75 mg daily dose) if ticagrelor is not an option, should be considered
as soon as the diagnosis is established.
IIa C
In patients with stable CAD, pre-treatment with clopidogrel may be considered if the probability of PCI is high. IIb C
Clopidogrel (600 mg loading dose, 75 mg daily dose) on top of aspirin is recommended in stable CAD patients under-
going coronary stent implantation and in ACS patients who cannot receive ticagrelor or prasugrel, including those with
prior intracranial bleeding or indication for OAC.20,23,39,40
I A
Clopidogrel (300 mg loading dose in patients aged <_75, 75 mg daily dose) is recommended on top of aspirin in STEMI
patients receiving thrombolysis.31,32
I A
Ticagrelor or prasugrel on top of aspirin may be considered instead of clopidogrel in stable CAD patients undergoing
PCI, taking into account the ischaemic (e.g. high SYNTAX score, prior stent thrombosis, location and number of
implanted stents) and bleeding (e.g. according to PRECISE-DAPT score) risks.
IIb C
In NSTE-ACS patients in whom coronary anatomy is not known, it is not recommended to administer prasugrel.25 III B
ACS = acute coronary syndrome; CAD = coronary artery disease; DAPT = dual antiplatelet therapy; NSTE-ACS = non-ST-elevation acute coronary syndrome; OAC = oral
anticoagulant; PCI = percutaneous coronary intervention; PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual
Anti Platelet Therapy; STEMI = ST-elevation myocardial infarction; SYNTAX = Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
aClass of recommendation.
bLevel of evidence.
cContraindications for ticagrelor: previous intracranial haemorrhage or ongoing bleeds. Contraindications for prasugrel: previous intracranial haemorrhage, previous ischaemic
stroke or transient ischaemic attack, or ongoing bleeds; prasugrel is not recommended for patients >_75 years of age or with a body weight <60 kg.
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outcome of 30-day net adverse clinical events (NACE) [MACE or
non-CABG BARC (Bleeding Academic Research Consortium) major
bleeding] was experienced in 9.8% and 11.7% of patients, respectively
(RR 0.83, 95% CI 0.73–0.96; P = 0.009). Radial access was associated
with a lower risk of all-cause mortality (1.6% vs. 2.2%; RR 0.72, 95% CI
0.53–0.99; P = 0.045). Major BARC 3 or 5 bleeding was significantly
reduced in the radial group (1.6% vs. 2.3%; RR 0.67, 95% CI 0.49–0.92;
P = 0.013). Radial access was associated with significantly lower rates
of surgical access site repair or transfusion of blood products. An
updated meta-analysis including MATRIX found a significant reduction
in major bleeds; death, MI, or stroke; and in all-cause mortality associ-
ated with radial as compared to femoral access.44
Aspirin dosing in patients treated with DAPT: Lower aspirin doses
(<_100 mg daily) have been consistently demonstrated to be associ-
ated with less major and total bleeding than higher doses, either
when used as monotherapy or when combined with the P2Y12 inhibi-
tor clopidogrel.45–52 This is because daily aspirin doses as low as
30–50 mg are able to completely inactivate the platelet cyclooxyge-
nase-1 enzyme and inhibit thromboxane production.53,54 In addition,
the efficacy of ticagrelor may be decreased in patients treated with
higher aspirin doses (>_300 mg daily) vs. lower aspirin doses
(<_100 mg daily).55 Although the molecular mechanism behind this
finding is not entirely clear, it reinforces the use of low dose aspirin.
The optimal range of aspirin dose in patients treated with DAPT that
provides maximal protection from ischaemic events and minimizes
bleeding risk appears to be 75–100 mg.
Platelet function testing, genetic testing, and switching of P2Y12 inhibitors:
High and low platelet reactivity on P2Y12 antagonist treatment pre-
dicts ischaemic and bleeding risks, respectively.56 These data have led
to the rationale for individualized antiplatelet therapy based on plate-
let function monitoring to identify the patients out of the expected
range of platelet inhibition.57 All randomized trials have failed to dem-
onstrate any benefit of platelet function monitoring to adjust
therapy.58–60 The low-risk level of the study populations, the exclu-
sive use of clopidogrel, and the P2Y12 reaction unit thresholds to
define the optimal window of P2Y12 inhibition have been recognized
as the main limitations of these trials.61–63
The Platelet Function Monitoring to Adjust Antiplatelet Therapy in
Elderly Patients Stented for an Acute Coronary Syndrome
(ANTARCTIC) trial has re-evaluated the concept of individualized
antiplatelet therapy by selecting only ACS patients at high risk of both
ischaemic and bleeding events (based on age >_75 years) and more
accurate thresholds in reflecting optimal P2Y12 inhibition.
Clopidogrel was replaced by prasugrel using the recommended daily
dose of 5 mg for the elderly, with the possibility of adjustment up and
down according to individual response. Platelet function monitoring
performed 14 days after discharge and later if needed led to a change
of treatment in 45% of patients who were identified as being over-
treated or undertreated by measurement of the P2Y12 inhibition
level; however, this strategy did not improve ischaemic or safety out-
comes.64 The influence of genetic variants on the response to antipla-
telet agents, especially clopidogrel, has been well-established in
patients with ACS and planned PCI.65 Rapidly-obtained genetic infor-
mation on the 2C19 genotype can help in reaching the optimal win-
dow of P2Y12 inhibition according to the cytochrome P450 (CYP)
2C19 profile,66,67 but no randomized trial has ever demonstrated any
clinical benefit of such an approach. Moreover, only 6–12% of the
variability in on-clopidogrel platelet reactivity can be explained by the
differences in genotype.68,69
For these reasons, neither platelet function testing nor genetic testing
can be recommended for tailoring DAPT. It may be considered in spe-
cific situations (e.g. patients suffering from recurrent adverse events) if
the results may change the treatment strategy. This is the case for
patients undergoing CABG who are exposed to DAPT (see Chapter 5).
Proton pump inhibitors and DAPT: Gastrointestinal haemorrhage is
the most common serious bleeding complication from the use of
long-term antiplatelet therapy.70 RCTs have shown that PPIs reduce
the rate of recurrent gastrointestinal bleeding in high-risk patients
receiving aspirin.71 Similar data exist regarding the use of famotidine,
a histamine H2-receptor antagonist.
72
Clopidogrel requires metabolic transformation in the liver by CYP
isoenzymes (mainly CYP2C19) to elicit its antiplatelet effect. PPIs are
also metabolized by CYP enzymes, leading to a potential inhibition of
CYP2C19 (mainly omeprazole and esomeprazole) translating into
reduced metabolic activation of clopidogrel when taken together.
Pharmacodynamic studies demonstrated the reduction of
clopidogrel-induced antiplatelet effects when a PPI, mainly omepra-
zole, was concomitantly administered.73–76 Based on drug–drug
interaction studies, omeprazole and esomeprazole would appear to
have the highest propensity for clinically relevant interactions, lanso-
prazole an intermediate probability, while pantoprazole and rabepra-
zole have the lowest.77 However, importantly, no interaction
between concomitant use of PPIs and prasugrel or ticagrelor has
been observed.
Only observational studies suggested an increased risk of cardio-
vascular ischaemic events when PPI therapy was administered con-
comitantly with clopidogrel.78 Conversely, randomized trials and
propensity score-matched studies did not support such
concerns.76,79–81
The Clopidogrel and the Optimization of Gastrointestinal Events
Trial (COGENT) was a randomized, double-blind, double-dummy,
placebo-controlled, phase III study of the efficacy and safety of a
fixed-dose combination of clopidogrel (75 mg) and omeprazole
(20 mg), as compared with clopidogrel alone.79 Patients were eligible
if they were 21 years of age or older and if the use of clopidogrel ther-
apy with concomitant aspirin was anticipated for at least the next
12 months, including patients presenting with an ACS or undergoing
placement of a coronary stent. Patients at high risk for gastrointestinal
bleeding were excluded (i.e. those in whom the need for a PPI, an H2-
receptor antagonist, sucralfate, or misoprostol was anticipated; with
pre-existing erosive oesophagitis or oesophageal or gastric variceal
disease or previous non-endoscopic gastric surgery; receipt of oral
anticoagulation therapy that could not be safely discontinued for the
duration of the study; or recent fibrinolytic therapy). Therefore, fol-
lowing previous evidence of benefit from a PPI or H2-receptor antag-
onist in high-risk patients treated with aspirin monotherapy, the
COGENT study included patients at low risk of gastrointestinal
bleeding undergoing DAPT, under the rationale that the risk of gas-
trointestinal bleeding is higher in patients taking aspirin and clopidog-
rel as compared to aspirin alone. This study was prematurely
stopped with a total of 3761 patients instead of the planned 5000 due
to financial reasons. The pre-specified primary gastrointestinal effi-
cacy endpoint was the time from randomization to the first occur-
rence of a composite of upper gastrointestinal clinical events, which
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.occurred in 1.1% of patients with omeprazole and 2.9% with placebo
at 180 days after randomization (HR 0.34, 95% CI 0.18–0.63; P <
0.001).79
Furthermore, there was no significant increase in the risk of cardio-
vascular events with concomitant use of clopidogrel and omeprazole
(4.9%, 95% CI 3.4–6.4%, in the omeprazole group; and 5.7%, 95% CI
4.0–7.3%, in the placebo group; P = 0.98), a finding that was consistent
even in high-risk subgroups and for individual endpoints. The rate of
serious adverse events did not differ significantly between the two
groups (10.1% with omeprazole and 9.4% with placebo, P = 0.48), nor
did the rate of overall adverse events (41.3 and 42.8%, respectively; P =
0.33). Diarrhoea was reported in 3.0% of patients receiving omepra-
zole, as compared with 1.8% of those receiving placebo (P = 0.01).
There were no newly diagnosed cases of osteoporosis. One case of
peripheral neuropathy was reported in the placebo group.
No randomized data comparing use vs. non-use of PPI in patients
taking aspirin and prasugrel or ticagrelor exist. However, the risk of
gastrointestinal bleeding is higher with DAPT in the form of prasu-
grel23 or ticagrelor82 as compared to clopidogrel. The short- and
long-term safety profile of PPIs has been well-established.79 Impaired
magnesium absorption with PPIs has been reported only from studies
in which patients had received a PPI for at least 1 year.83
Magnesaemia monitoring is recommended at follow-up, especially
for longer than 1 year of therapy.
Type, dose of P2Y12 inhibitor, and duration of treatment: The type and
dose of P2Y12 inhibitor are well-established according to the various set-
tings of CAD. Previous intracranial haemorrhage or ongoing bleeds are
common contraindications for prasugrel and ticagrelor, while prasugrel
should be given with caution in patients >_75 years of age or with a body
weight <60 kg. Patients with previous stroke or transient ischaemic
attack (TIA) may derive harm from prasugrel instead of clopidogrel.23
Prior stroke is a marker of frailty and of subsequent risk of haemorrhagic
stroke, especially during the first year thereafter. Switching from prasu-
grel or ticagrelor to clopidogrel is a common practice, especially in cases
of minor bleeding or in patients with low platelet reactivity, a marker of
major bleeding risk.56,84,85 There are no properly powered randomized
data on the long-term safety or efficacy of ‘switching’ patients treated
for weeks or months with a P2Y12 inhibitor to a different P2Y12 inhibi-
tor. Therefore, this practice is generally discouraged.
3.8 Switching between oral P2Y12
inhibitors
Differences in the pharmacology of P2Y12 receptor inhibitors with
regard to their binding site, half-life, and speed of onset and offset of
action are important factors that might lead to drug interactions
when switching from one agent to another.
The transition from clopidogrel to ticagrelor is the only switch
between P2Y12 inhibitors that has been investigated in a trial pow-
ered for clinical endpoint, even if the study was not specifically
designed to assess the safety and efficacy of the transition from clo-
pidogrel to ticagrelor. In PLATO, nearly 50% of patients randomly
allocated to receive ticagrelor had been pre-treated with clopidog-
rel, mostly given as a 300–600 mg loading dose.20 The efficacy and
safety of ticagrelor were not affected by previous clopidogrel expo-
sure.88 On the other hand, the TRITON-TIMI 38 trial mandated
that previous exposure of patients to a P2Y12 receptor inhibitor
Measures to minimize bleeding while on dual antiplatelet therapy
Recommendations Classa Levelb
Radial over femoral access is recommended for coronary angiography and PCI if performed by an expert radial operator.43,44 I A
In patients treated with DAPT, a daily aspirin dose of 75 - 100 mg is recommended.45–47,51,52 I A
A PPI in combination with DAPTc is recommended.70,79,80,86,87 I B
Routine platelet function testing to adjust antiplatelet therapy before or after elective stenting is not recommended.58–60 III A
DAPT = dual antiplatelet therapy; PCI = percutaneous coronary intervention; PPI proton pump inhibitor.
aClass of recommendation.
bLevel of evidence.
cWhile the evidence that a PPI does not increase the risk of cardiovascular events was generated with omeprazole, based on drug–drug interaction studies, omeprazole and
esomeprazole would appear to have the highest propensity for clinically relevant interactions, while pantoprazole and rabeprazole have the lowest.
Switching between oral P2Y12 inhibitors
Recommendations Classa Levelb
In patients with ACS who were previously
exposed to clopidogrel, switching from clopi-
dogrel to ticagrelor is recommended early
after hospital admission at a loading dose of
180 mg irrespective of timing and loading
dosec of clopidogrel, unless contraindications
to ticagrelor exist.20
I B
Additional switching between oral P2Y12
inhibitors may be considered in cases of
side effects/drug intolerance according to
the proposed algorithms.
IIb C
ACS = acute coronary syndrome.
aClass of recommendation.
bLevel of evidence.
cContraindications for ticagrelor: previous intracranial haemorrhage or ongoing
bleeds.
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..should be an exclusion criterion for study entry.23 While registry data
provide reassuring information with respect to the safety profile of
switching from clopidogrel to prasugrel,89–91 no randomized data exist
in the setting of studies powered for clinical endpoint. Similarly, all
other switching possibilities, including between prasugrel and tica-
grelor or from ticagrelor/prasugrel to clopidogrel, have not been
investigated with outcome data.92–94 This practice is therefore dis-
couraged due to a lack of safety/efficacy data. As the need to switch
between P2Y12 inhibitors may arise for clinical reasons (i.e. side
effects or drug intolerance), and registry data indicate that switch-
ing is not infrequent in practice, switching algorithms based on
pharmacodynamic studies are provided (Figure 2).
4. Dual antiplatelet therapy and
percutaneous coronary
intervention
An overview of all studies investigating the benefits and risks
of DAPT duration beyond 1 month, largely focusing on post-
PCI patients or those with prior ACS, is shown in Web addenda
Table S1 (A and B). An overview of recommendations endorsed
by these guidelines regarding DAPT duration after PCI, as well as
after CABG or in medically managed ACS patients, is provided in
Figure 3.
4.1 Dual antiplatelet therapy after
percutaneous coronary intervention for
stable coronary artery disease
DAPT is not indicated in purely medically managed patients (i.e. with-
out prior PCI) with stable CAD and no history of prior MI. The
Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance (CHARISMA) study
included patients with stable vascular disease or at risk of athero-
thrombotic events, and showed that clopidogrel plus aspirin was not
significantly more effective than aspirin alone in reducing the rate of
MI, stroke, or death from cardiovascular causes.95
After PCI with stent placement, DAPT is the standard of care. The
Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial2 and,
subsequently, other studies96,97 established the 1-month course of
DAPT after bare-metal stent (BMS). An arbitrary 12-month or more
DAPT duration has been subsequently recommended based on expert
opinions after first generation DES, irrespective of clinical presentation.
No dedicated study exists focusing on stable CAD patients under-
going PCI and being exposed to different DAPT durations. Hence,
recommendations regarding stable CAD patients undergoing PCI
derive from subgroup analyses from pertinent RCTs (Figure 4).98,99
While no RCTs investigating the use of ticagrelor or prasugrel
instead of clopidogrel in stable CAD patients undergoing PCI exist, this
treatment option may be considered in selected patients in whom the
use of clopidogrel is unsatisfactory based on prior clinical outcomes or
potentially associated with higher risk of ischaemic events that bleeding
recurrences.
Three- or 6- vs. at least 12-month DAPT duration: The Efficacy of
Xience/Promus Versus Cypher to Reduce Late Loss After
Stenting (EXCELLENT) trial compared a 6-month DAPT [acetyl-
salicylic acid (ASA) þ clopidogrel] duration with 1-year DAPT
after DES.100 With 1443 patients randomized, the rates of target
vessel failure—defined as the composite of cardiac death, MI, or
ischaemia-driven target vessel revascularization—at 12 months
were 4.8% in the 6-month DAPT group and 4.3% in the 12-month
DAPT group (P = 0.001 for non-inferiority). There was a numeri-
cally lower risk of bleeding in the short DAPT arm (HR 0.50, 95%
CI 0.09–2.73). There was no signal of heterogeneity for the pri-
mary study endpoint with respect to clinical presentation (i.e. sta-
ble CAD, n = 699 patients vs. ACS, n = 744 patients). The
PROlonging Dual antiplatelet treatment after Grading stent-
induced intimal hYperplasia (PRODIGY) trial randomized 2013
patients101 to 6 or 24 months of DAPT (ASA þ clopidogrel) and
to one of four stent types (a four-by-two factorial design), includ-
ing BMS and three different DES types. The 2-year incidence of all-
cause death, MI, and stroke or cerebrovascular accident was
10.1% with 24-month DAPT compared with 10.0% with 6-month
DAPT (P = 0.91). There was a lower risk of major bleeding with
shorter DAPT based on both the BARC (1.9% vs. 3.4%; HR 0.56,
95% CI 0.32–0.98; P = 0.037) or the TIMI scale (0.6% vs. 1.6%; HR
0.38, 95% CI 0.15–0.97; P = 0.041). After censoring events that
occurred after 12 months, while keeping the original randomiza-
tion design, the risk of TIMI major bleeding was 0.5% in the short-
term DAPT arm vs. 0.9% in the long-term DAPT arm (HR 0.56,
95% CI 0.19–1.66). In this trial, a total of 1465 (74.3%) patients
presented with ACS whereas 505 (25.7%) had stable CAD.99 No
heterogeneity was noted with respect to the primary efficacy end-
point. There was a borderline quantitative interaction between
clinical presentations and bleeding outcomes (P values for interac-
tion = 0.056 for BARC 2, 3, or 5; P = 0.091 for BARC 3 or 5), sug-
gesting a higher hazard of bleeding in the 24-month DAPT arm
when compared with the 6-month arm in the stable CAD patients,
which was not observed in the ACS patients.99 Analysis of
NACE—consisting of death, MI, cerebrovascular accident, or
BARC 2, 3, or 5 bleeding—revealed significant harm from
extended DAPT in stable CAD patients (NACE in the 24-month
vs. 6-month DAPT arm: 13.3% vs. 5.6%; HR 2.5, 95% CI 1.35–4.69,
P = 0.004; NNT for harm = 13) and no benefit in the ACS popula-
tion (16.1% vs. 14.1%; HR 1.15, 95% CI 0.88–1.50; P = 0.29), with
positive quantitative interaction testing (P value for interaction =
0.024).99 Patients with high CRUSADE (Can Rapid risk stratifica-
tion of Unstable angina patients Suppress ADverse outcomes with
Early implementation of the ACC/AHA Guidelines) bleeding risk
score treated with 24-month DAPT experienced a threefold
higher risk of major bleeding and a fivefold risk of red blood cell
transfusion as compared with 6-month therapy, without clear evi-
dence of benefit.13
In 2014, three additional randomized studies were published
that compared 6 months of DAPT to 12 or 24 months of DAPT
(ASA þ clopidogrel): Is There a Life for DES After
Discontinuation of Clopidogrel (ITALIC),102 Second Generation
Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-
Month Dual Antiplatelet Therapy (SECURITY),103 and
Intracoronary Stenting and Antithrombotic Regimen: Safety and
Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting
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Stenting (ISAR-SAFE).104 ISAR-SAFE was the largest of these three
studies, with 4005 randomized patients, and the only double-blind
investigation. It confirmed that a 12-month course of DAPT did
not afford any benefit over a 6-month course with respect to
ischaemic endpoints. Likewise, the net clinical benefit (composite
of death, MI, stent thrombosis, stroke, and TIMI major bleeding)
was neutral. At subgroup analysis, there was no signal of heteroge-
neity with respect to the primary study endpoint among the 2394
patients who presented with stable CAD as opposed to the 1601
patients with ACS.104 Consistent results were shown in the
ITALIC and SECURITY trials. Two studies, Real Safety and Efficacy
of 3-Month Dual Antiplatelet Therapy Following Endeavor
Zotarolimus-Eluting Stent Implantation (RESET)105 and
Optimized Duration of Clopidogrel Therapy Following Treatment
With the Zotarolimus-Eluting Stent in Real-World Clinical
Practice (OPTIMIZE),106 investigated a 3-month duration of
DAPT (ASA þ clopidogrel). RESET randomized 2117 patients to
3- or 12-month duration of DAPT and did not show significant
Ticagrelor MD (90 mg b.i.d.)
24h after last Prasugrel dose
Figure 2 Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. LD = loading dose; MD = maintenance dose.
Colour-coding refers to the ESC Classes of Recommendations (green = Class I; orange = Class IIb). The green arrow from clopidogrel to ticagrelor
highlights the only switching algorithm for which outcome data are available in patients with acute coronary syndrome. No outcome data (orange
arrows) are available for all other switching algorithms. Acute setting is considered as a switching occurring during hospitalization.
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Figure 4 Algorithm for dual antiplatelet therapy (DAPT) in patients treated with percutaneous coronary intervention. ACS = acute coronary syn-
drome; BMS = bare-metal stent; BRS = bioresorbable vascular scaffold; CABG = coronary artery bypass graft surgery; DCB = drug-coated balloon;
DES: drug-eluting stent; PCI = percutaneous coronary intervention; Stable CAD = stable coronary artery disease.
High bleeding risk is considered as an increased risk of spontaneous bleeding during DAPT (e.g. PRECISE-DAPT score >_25).
Colour-coding refers to the ESC Classes of Recommendations (green = Class I; yellow = IIa; orange = Class IIb).
Treatments presented within the same line are sorted in alphabetic order, no preferential recommendation unless clearly stated
otherwise.
1: After PCI with DCB 6 months. DAPT should be considered (Class IIa B).
2: If patient presents with Stable CAD or, in case of ACS, is not eligible for a treatment with prasugrel or ticagrelor.
3: If patient is not eligible for a treatment with prasugrel or ticagrelor.
4: If patient is not eligible for a treatment with ticagrelor.
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harm with the shortened period (composite rates of any death,
MI, or stent thrombosis 0.8% vs. 1.3%; P = 0.48). Similar results
were achieved in OPTIMIZE with 3119 patients randomized. In
this study, the 1-year incidence of MACE was 8.3% in the short-
term group and 7.4% in the long-term group (HR 1.12, 95% CI
0.87–1.45). Both studies mandated the use of the Endeavor
zotarolimus-eluting stent (ZES) in the 3-month DAPT arms, which
is no longer available on the market. It is not clear to what extent
the results of RESET and OPTIMIZE are applicable to other types
of DES.
Palmerini et al performed a meta-analysis addressing the outcome
of a <_6-month course of DAPT vs. a 1-year course after DES.107 The
1-year course of therapy did not confer any advantage over the
shorter course of DAPT with respect to survival, stent thrombosis,
or MI, but it increased the risk of major bleeding substantially. Similar
results were obtained by other meta-analyses.108,109
Twelve-month vs. >12-month DAPT duration: Following the pro-
posed landmark of 12 months as the standard DAPT duration
after DES, the DAPT trial investigated whether further extension
of DAPT might be beneficial.110 The DAPT study enrolled patients
who, at 12 months after placement of a DES, were still on DAPT
and had not suffered an ischaemic or bleeding event. Patients
were randomly allocated to thienopyridine or placebo for another
18 months. Aspirin was maintained throughout the study period.
Thirty-month DAPT as compared with 12-month DAPT
reduced the rates of stent thrombosis (0.4% vs. 1.4%; P < 0.001)
and of major adverse cardiac and cerebrovascular events
(MACCE) (4.3% vs. 5.9%; P < 0.001). This included a substantial
reduction in the rate of MI (2.1% vs. 4.1%; P < 0.001); slightly
more than half of this benefit could be attributed to the preven-
tion of spontaneous MIs (see chapter 3.2). This ischaemic protec-
tion came at the cost of an increased risk of bleeding (GUSTO
moderate or severe bleeding 2.5% vs. 1.6%, P < 0.001) and an
increase in total mortality with borderline statistical significance
(see section 3.3).
Of 11 648 randomized patients within the DAPT trial (9961
treated with DES and 1687 with BMS), 30.7% presented with MI.98
The excess of mortality observed within the 30-month DAPT arm
was entirely driven by fatalities, which occurred in patients without
prior MI (2.1% for continued thienopyridine group vs. 1.5% for pla-
cebo; HR 1.43, 95% CI 1.02–2.00; P = 0.04). Yet, the interaction
P value did not reach statistical significance (effect for MI vs. no MI
interaction P = 0.13).99
Three independent meta-analyses, which included 5045 patients
recruited within DES-Late coronary Arterial Thrombotic Events
(LATE)111 and 1259 patients from the Assessment by a Double
Randomisation of a Conventional Antiplatelet Strategy Versus a
Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and,
of Treatment Interruption Versus Continuation 1 Year After
Stenting-Interruption (ARCTIC-Interruption) trial,112 provided
results consistent with a possible increase in mortality with pro-
longed DAPT as shown in the DAPT trial. A more recent meta-
analysis of 11 RCTs that enrolled 33 051 patients who received pre-
dominantly newer-generation DES also provided weak evidence of
an increased mortality rate with prolonged DAPT.113
Thus, if DAPT is administered for a sufficient length of time after
placement of DES for stable CAD, a substantial benefit in terms of
secondary prevention and reduction of stent thrombosis emerges.
However, this benefit is counterbalanced by an increased risk of
bleeding and by a signal for increased mortality. Thus, systematic
extension of DAPT beyond six months is not justified for all patients
but should be based on the individual risk profile of the patient (see
section 3.5).
Impact of type of DES on duration of DAPT: The benefit of
extended periods of DAPT varies with stent type. However, there
are differences between first- and newer-generation DES. In
PRODIGY, only patients with the paclitaxel-eluting stent benefit-
ted from extended DAPT with a significant reduction of the risk of
stent thrombosis.114 Likewise, in DAPT, the benefit of extended
DAPT was largest with patients with a paclitaxel-eluting stent and
the smallest with an everolimus-eluting stent.110,115 There also was
a significant interaction between stent type and benefit of
extended DAPT with respect to MACCE.110 With an everolimus-
eluting stent, the 1-year NNT for prevention of stent thrombosis
was 157, whereas the 1-year NNT for harm for moderate or
severe bleeding was 56.115 In the meta-analysis by Giustino et al,109
the reduction of stent thrombosis by extended DAPT was signifi-
cantly reduced with new-generation stents as compared with first-
generation DES, and statistical significance was lost within the
new-generation subset. No such interaction was found concerning
bleeding complications. Similar results were obtained in two other
meta-analyses (Sharma et al116 and Palmerini et al117).
Bioresorbable stents and drug-coated balloons: No dedicated stud-
ies examining the optimal duration of DAPT after implantation of a
bioresorbable scaffold currently exist. In the largest randomized
clinical trial investigating the treatment of patients with a poly-lac-
tic acid-based bioresorbable scaffold, DAPT was recommended
for at least 12 months.118 However, meta-analysis has shown evi-
dence of an approximately twofold higher rate of stent thrombosis
in comparison with conventional DES, especially in the first 30
days after implantation.119 This provides a rationale for considering
more potent P2Y12 inhibitors in these patients. In addition, some
concerns have been raised regarding late stent thrombosis beyond
1 year after implantation120,121 and a longer duration of DAPT
therapy may be advocated, at least in patients at low bleeding risk.
No large-scale clinical trials are available concerning magnesium-
based bioresorbable scaffolds.
In patients treated with drug-coated balloons, dedicated clinical tri-
als investigating the optimal duration of DAPT are lacking. In patients
treated for in-stent restenosis, the largest randomized trials investi-
gating drug-coated balloon therapy have recommended a treatment
duration of between 3 - 12 months.122–124 In addition, some small
clinical trials, as well as larger registries, including patients with stable
CAD undergoing drug-coated balloon angioplasty have recom-
mended DAPT duration of at least 1 month.125
Plain old balloon angioplasty: no data on DAPT or DAPT duration
exist after plain old balloon angioplasty, which is currently
reserved for a small minority of patients in whom stent implanta-
tion is not feasible (e.g. small calibre vessel or extreme vessel tor-
tuosity) or desirable (e.g. to avoid DAPT in patients referred to
CABG). The institution of DAPT and its duration, if implemented,
should depend on clinical profile (ischaemic vs. bleeding risks)
and/or the reasons (e.g. planned surgery) for avoiding stent
implantation.
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4.2 Dual antiplatelet therapy after
percutaneous coronary intervention for
acute coronary syndrome
DAPT with novel P2Y12 inhibitors for 1 year after PCI for ACS: The evi-
dence supporting the value of the combination of aspirin and clopi-
dogrel in patients with ACS has been extensively reviewed in
previous guidelines (NSTE-ACS), and data supporting the superiority
of ticagrelor and prasugrel over clopidogrel in this setting are dis-
cussed in section 3.6.
Although both prasugrel and ticagrelor significantly increase the
risk of TIMI major non-CABG related bleeds, the risk–benefit ratios
were favourable with NNT for benefit of 46 and 53, respectively, and
NNT for harm of 167 for both agents. These data established the 1-
year course of DAPT, preferably with prasugrel or ticagrelor, for
patients undergoing PCI for ACS, unless there are contraindications
(Figure 4).
Mounting evidence for secondary prevention by intensified antiplatelet
therapy: In patients presenting with ACS, the cardiovascular risk
remains substantially elevated beyond the first year, even if successful
revascularization has been achieved. In this setting, intensified antipla-
telet therapy on top of aspirin has been shown to be an effective
therapeutic strategy to prevent recurrent ischaemic events.
However, the risk–benefit ratios seem less favourable than those
observed in studies assessing <_1-year DAPT duration. Relevant infor-
mation has been provided by the prior MI patient subsets included in
the CHARISMA135 (n = 3846) and DAPT98 (n = 3576) trials, which
mainly compared clopidogrel with placebo on top of aspirin; by the
subset of patients who underwent coronary angiography within the
TRILOGY136 trial, which compared prasugrel with clopidogrel; and
by the patients with prior MI within the Thrombin Receptor
Antagonist in Secondary Prevention of Atherothrombotic Ischemic
Events (TRA 2P-TIMI 50)137 (n = 17 779 ) trial, which compared
vorapaxar with placebo. Taken separately, these trial results are diffi-
cult to interpret because they are based on subgroup analyses.
Moreover, CHARISMA and TRILOGY had a neutral main outcome
and the main results of TRA 2P-TIMI 50 showed an unfavourable
risk–benefit ratio. Therefore, a dedicated trial on prolonged DAPT
for secondary prevention after ACS was needed. The PEGASUS trial
filled this gap.29
DAPT with ticagrelor for secondary prevention after MI: PEGASUS
recruited 21 162 patients with spontaneous MI 1–3 years before
enrolment, who were at >_50 years old and had at least one additional
high-risk feature: age >_65 years, diabetes mellitus, a second spontane-
ous MI, multivessel CAD, or chronic renal dysfunction.29 The patients
were randomly assigned to ticagrelor 90 mg b.i.d., ticagrelor 60 mg
b.i.d., or placebo. All the patients received low-dose aspirin. Of the
patients included in PEGASUS, 53% were enrolled after a STEMI and
83% were previously treated by PCI. The primary efficacy endpoint
was the composite of cardiovascular death, MI, or stroke at 3 years
and was 7.85% in the 90 mg arm, 7.77% in the 60 mg arm, and 9.04%
in the placebo arm (P = 0.008 and P = 0.004 for the higher and lower
doses, respectively, vs. placebo).29 There was a consistent reduction
in all components of the primary endpoint with ticagrelor vs. placebo,
which reached statistical significance for MI with both doses of tica-
grelor and for stroke with the lower dose. There was also a trend for
a reduction in cardiovascular mortality. Due to a non-significant yet
numerical increase in non-cardiovascular deaths in the two ticagrelor
arms, the outcome was neutral with respect to all-cause death. The
primary safety endpoint of TIMI major bleeding was observed more
frequently with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg)
than with placebo (1.06%) (P < 0.001 for each dose vs. placebo). The
NNT for benefit for the primary endpoint was 250 for the 90 mg
Dual antiplatelet therapy duration and related stent
choices in patients with stable coronary artery disease
treated with percutaneous coronary intervention
Recommendations Classa Levelb
In patients with stable CAD treated with
coronary stent implantation, DAPT consist-
ing of clopidogrel in addition to aspirin is
generally recommendedc for 6 months, irre-
spective of the stent type.100,101,104,126–130
I A
Irrespective of the intended DAPT duration,
DESc is the preferred treatment option.129–132
I A
In patients with stable CAD considered at high
bleeding risk (e.g. PRECISE-DAPT >_25), DAPT
for 3 monthsd should be considered.105,106
IIa B
In patients with stable CAD treated with
drug-coated balloon, DAPT for 6 months
should be considered.122,124,133
IIa B
In patients with stable CAD treated with
bioresorbable vascular scaffolds, DAPT for
at least 12 months should be considered.
IIa C
In patients with stable CAD who have toler-
ated DAPT without a bleeding complication
and who are at low bleeding but high throm-
botic risk, continuation of DAPT with clopi-
dogrel for >6 months and <_30 months may
be considered.26,107–109
IIb A
In patients with stable CAD in whom 3-
month DAPT poses safety concerns, DAPT
for 1 monthe may be considered.
IIb C
BMS = bare-metal stent; CAD = coronary artery disease; DAPT = dual antiplate-
let therapy; DES = drug-eluting stent; MI = myocardial infarction; PRECISE-DAPT
= PREdicting bleeding Complications In patients undergoing Stent implantation
and subsEquent Dual Anti Platelet Therapy.
aClass of recommendation.
bLevel of evidence.
cThese recommendations refer to stents that are supported by large-scale
randomized trials with clinical endpoint evaluation leading to unconditional CE
mark, as detailed in Byrne et al.134
dThe evidence supporting this recommendation comes from two studies where
zotarolimus-eluting Endeavour sprint stent has been investigated in conjunction
with a 3-month DAPT regimen.
e1-month DAPT following implantation of zotarolimus-eluting Endeavour sprint stent
or Biofreedom drug-coated stent reduced risks of re-intervention, myocardial infarc-
tion and inconsistently of stent thrombosis compared to bare-metal stent under simi-
lar DAPT duration.129,130 It is unclear if this evidence applies to other contemporary
DES.
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..dose and 238 for the 60 mg dose; the corresponding NNT for harm
was 244 and 322, respectively, with the two ticagrelor doses.29
With the 90 mg dose, the absolute benefit in terms of the primary
efficacy endpoint was in the same order as the absolute harm in
terms of the primary safety endpoint, and with 60 mg the absolute
benefit was only marginally larger than the absolute harm. However,
the relevance of the various endpoints to the patient’s overall well-
being may differ and are, therefore, difficult to weigh against one
another. The impact of MI and bleeding on mortality was comparable
in previous studies.11,138 A post hoc analysis from the Thrombin
Receptor Antagonist for Clinical Event Reduction in Acute Coronary
Syndrome (TRACER) trial suggested that while bleeding according to
BARC 2 and 3a criteria was less prognostic for death than MI, the risk
of mortality was equivalent between BARC 3b bleeding and MI, and
was higher following BARC 3c bleeding. Moreover, at variance with
previous analyses, both MI and bleeding impacted mortality with simi-
lar time dependency.42 In view of these consistent findings through-
out multiple independent studies, both the efficacy and the safety
endpoints deserve attention, as both most likely similarly impact
mortality. With this background, the narrow risk–benefit ratio cau-
tions against the universal long-term administration of ticagrelor for
secondary prevention after MI, and calls for individualized treatment
decisions based on ischaemic and haemorrhagic risk.
To this end, patients who continued their thienopyridine treat-
ment without (a major) interruption (<_30 days) derived a larger
benefit from extended ticagrelor intake than patients who inter-
rupted their thienopyridine treatment for longer periods of
time.139 Depending on the actual discontinuation time frame of
previous thienopyridine therapy, the HRs (95% CI) of the primary
endpoint for ticagrelor (pooled doses) vs. placebo were 0.73
(0.61–0.87) for those who continued within 30 days, 0.86
(0.71–1.04) for those who interrupted for 30 days to 1 year, and
1.01 (0.80–1.27) for those who interrupted for more than 1 year
(P trend for interaction < 0.001).139 There was no significant inter-
action of timing with the effect of ticagrelor on bleeding risk. These
findings suggest that patients who can continue their initial thieno-
pyridine treatment are those deriving relatively greater benefit
from DAPT continuation with ticagrelor. Nevertheless, even in
this patient subset, the absolute increase in TIMI major bleeding
associated with extended ticagrelor was similar in magnitude as
compared to the absolute decrease in the composite ischaemic
endpoint (i.e. 1.9 percentage point difference for both the safety
and the efficacy endpoints).139
Patients with lower-extremities artery disease (LEAD), who are
known to be at greater ischaemic risk, also derived heightened bene-
fit from extended ticagrelor.140 In these patients, the absolute
decreases in the primary efficacy endpoint achieved by ticagrelor vs.
placebo were 3.0% for the 90 mg dose and 5.2% for the 60 mg dose,
whereas the increases in TIMI major bleeding were only 0.22% and
0.02%, respectively. In addition, ticagrelor was significantly associated
with fewer events related to LEAD (i.e. acute limb ischaemia and
peripheral revascularization procedures).
DAPT with thienopyridines (clopidogrel or prasugrel) for secondary pre-
vention after MI: In the DAPT trial, 3567 patients had initially pre-
sented with MI.98 A non-prespecified analysis of these patients
investigated whether the benefits and risks of extended vs. standard
duration of DAPT was similar among patients with or without MI.
The active comparator was prasugrel in one-third of the patients
with MI and clopidogrel in two-thirds of the patients.
In patients with MI, extended DAPT as compared with aspirin
alone reduced stent thrombosis significantly (0.5% vs. 1.9%; P <
0.001). There also was a significant reduction of MACCE by extended
DAPT (3.9% vs. 6.8%; P < 0.001). This included a major reduction in
the rate of recurrent MI (2.2% vs. 5.2%; P < 0.001). On the other side,
GUSTO moderate or severe bleeding was significantly increased by
extended DAPT (1.9% vs. 0.8%, P = 0.005). Contrary to the main
study, all-cause mortality was similar in the extended DAPT group as
compared with the placebo group (1.4% vs. 1.6%; P = 0.61), even if
formal interaction testing was inconclusive.
A meta-analysis on the effect of extended DAPT in patients
with previous MI comprising PEGASUS and MI subgroups of stud-
ies with thienopyridines—CHARISMA, PRODIGY, and DES-
LATE with clopidogrel as well as ARCTIC-Interruption and DAPT
with clopidogrel or prasugrel—has been recently published.141
Extended DAPT decreased the risk of MACCE compared with
aspirin alone (6.4% vs. 7.5%; P = 0.001). There was a consistent sig-
nificant reduction in each component of the primary endpoint (RR
0.85, 95% CI 0.74–0.98 for cardiovascular death; RR 0.70, 95% CI
0.55–0.88 for MI; RR 0.81, 95% CI 0.68–0.97 for stroke). This ben-
efit was achieved at the cost of a significantly increased risk of
major bleeding (1.85% vs. 1.09%; P = 0.004). Although the reduc-
tion in cardiovascular mortality associated with prolonged DAPT
was significant, the absolute risk reduction was small (0.3%). In
addition, there was no difference in all-cause mortality (4.0% in
the extended DAPT group and 4.2% in the aspirin alone group).
No significant difference between study heterogeneity was identi-
fied across the appraised endpoints. This may suggest a consistent
class effect among the three P2Y12 inhibitors (clopidogrel, ticagre-
lor, or prasugrel). However, caution should be used in interpreting
this finding, taking into account that the PEGASUS study alone
contributed >_60% to pooled endpoint estimates and that
PEGASUS was the only trial included in its totality (and as such the
only properly powered study for post-MI patients), whereas post
hoc subgroups of patients recruited in the other four investigations
were pooled. In addition, when the overall included populations
of the four available studies assessing DAPT for >1 year vs. 12-
month therapy are pooled, an extended treatment with ticagrelor,
as compared to a similar strategy with thienopyridines, exerted a
more favourable effect on all-cause mortality due to a trend
towards reduction of cardiovascular death and a null effect on
non-cardiovascular death.142 Finally, PEGASUS was the only trial
that allowed patients who had stopped DAPT months or years
before to randomly restart therapy; this likely resulted in relatively
lower efficacy endpoint estimates as compared to other studies
testing duration of thienopyridines where treatment was either
permanently stopped or continued without treatment interrup-
tions in between. Therefore, it is reasonable to favour ticagrelor
60 mg b.i.d. as the agent of choice for prolonging DAPT beyond
12 months in stabilized post-MI patients at low bleeding risk, and
to reserve the use of clopidogrel (or prasugrel, the least investi-
gated agent in this setting) as the alternative choice if ticagrelor
therapy is not tolerated or feasible.
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..Shortening of DAPT duration in patients at high bleeding risk: There is
no dedicated RCT assessing the optimal DAPT duration in patients at
high bleeding risk. Moreover, many, if not all, available DAPT studies
formally excluded these patients from inclusion. The Zotarolimus-
eluting Endeavor sprint stent in Uncertain DES Candidates (ZEUS)
and the Prospective randomized comparison of the BioFreedom biol-
imus A9 drug-coated stent versus the gazelle BMS in patients at high
bleeding risk (LEADERS-FREE) studies recruited a selected high
bleeding risk population and randomized them to BMS or drug-
coated stent under a protocol-mandated DAPT duration of
1 month.129,130 Both studies, as discussed in section 2.4, proved the
superiority of the investigated DES technologies as compared to BMS
despite a similarly short duration of DAPT. The trade-off between
bleeding prevention and ischaemic protection of prolonging DAPT
beyond 1 month in this patient subset remains unclear.
As discussed in section 4.1, two studies compared 3- vs. 12-month
DAPT duration after DES. Patients were not selected based on high
bleeding risk criteria and both studies included only a minority of
patients presenting with acute MI (14.3 and 5.4% in the RESET and
OPTIMIZE trials, respectively).105,106
After an ACS, high bleeding risk status poses even greater
challenges with respect to the choice of DAPT duration. The
risks of shortening DAPT below 1 year have been addressed by
an individual patient data meta-analysis.143 This meta-analysis
comprised six trials comparing three- or six-month DAPT with
12-month DAPT including 11 473 patients, 4758 of whom had
ACS. In patients with ACS, shortening DAPT to <_ 6 months was
associated with an estimated increase in the risk of MI or defi-
nite/probable stent thrombosis from 1.7% to 2.4% compared
with 1-year DAPT. Although this increase did not reach statisti-
cal significance (HR 1.48, 95% CI 0.98–2.22; P = 0.059), it has
to be kept in mind that the power of this analysis was limited
since the number of patients with ACS included was roughly
only one-third or one-fourth of that in TRITON or PLATO,
which established the superiority of intensified antiplatelet ther-
apy over conventional 1-year DAPT with clopidogrel. Despite
this limitation, it is probably fair to conclude that the ischaemic
risk of shortening DAPT to 6 months after PCI in ACS is low,
although not negligible. In this respect, it is also reassuring that
there was no signal with respect to cardiac or all-cause death
(HR 0.75, 95% CI 0.45–1.27 and HR 0.85, 95% CI 0.58–1.26,
respectively). Only when DAPT duration was reduced to
3 months did the risk of MI and definite/probable stent throm-
bosis increase substantially (HR 2.08, 95% CI 1.10–3.93).
In summary, currently available evidence suggests considering
discontinuation of P2Y12 inhibitor therapy after 6 months, when
the risk of bleeding is high.
4.3 Gaps in the evidence
With a marginal overall benefit-to-risk ratio of extended DAPT beyond
1 year after DES placement, tools to identify ideal candidates for long-
term or even indefinite DAPT duration are critically needed. The DAPT
score15 as well as the subgroup analyses of PEGASUS139,140,144,145 are
important steps forward, but prospective validation in contemporary
cohorts of newer-generation DES patients is needed.
Dual antiplatelet therapy duration in patients with acute coronary syndrome treated with percutaneous coronary
intervention
Recommendations Classa Levelb
In patients with ACS treated with coronary stent implantation, DAPT with a P2Y12 inhibitor on top of aspirin is rec-
ommended for 12 months unless there are contraindications such as excessive risk of bleeding (e.g. PRECISE-DAPT
>_25).20,23,40
I A
In patients with ACS and stent implantation who are at high risk of bleeding (e.g. PRECISE-DAPT >_25), discontinua-
tion of P2Y12 inhibitor therapy after 6 months should be considered.
13,18,143 IIa B
In patients with ACS treated with bioresorbable vascular scaffolds, DAPT for at least 12 months should be
considered.
IIa C
In patients with ACS who have tolerated DAPT without a bleeding complication, continuation of DAPT for longer
than 12 months may be considered.26,139
IIb A
In patients with MI and high ischaemic riskc who have tolerated DAPT without a bleeding complication, ticagrelor
60 mg b.i.d. for longer than 12 months on top of aspirin may be preferred over clopidogrel or prasugrel.29,115,142
IIb B
ACS = acute coronary syndrome; b.i.d. = bis in die; DAPT = dual antiplatelet therapy. MI = myocardial infarction; PRECISE-DAPT = PREdicting bleeding Complications In
patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy.
aClass of recommendation.
bLevel of evidence.
cDefined as >_ 50 years of age, and one or more of the following additional high-risk features: age of 65 years or older, diabetes mellitus requiring medication, a second prior
spontaneous myocardial infarction, multivessel coronary artery disease, or chronic renal dysfunction, defined as an estimated creatinine clearance < 60 mL/min.
These recommendations refer to stents that are supported by large-scale randomized trials with clinical endpoint evaluation leading to unconditional CE mark, as detailed in
Byrne et al.134
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The optimal level of platelet inhibition during the various stages of
CAD remains an open question. The risk of ischaemic complication is
highest immediately after PCI and then gradually declines. The same
is true for patients managed for ACS, although the risk remains ele-
vated above that of patients who never experienced an acute exacer-
bation for years. Thus, it is intuitive that during the chronic phase
after stabilization the level of platelet inhibition may be reduced as
compared with the acute phase. Until recently, there were only lim-
ited data addressing this issue from beyond the periprocedural phase
to 1 year. By now, two studies addressing such a step-down concept
have finished recruitment: Testing Responsiveness to Platelet
Inhibition on Chronic Antiplatelet Treatment For Acute Coronary
Syndromes Trial (TROPICAL-ACS) (NCT01959451) with a step-
down from prasugrel to clopidogrel after the peri-interventional
phase in acute MI; and GLOBAL-LEADERS (NCT01813435)146 with
a step-down from DAPT to single antiplatelet therapy with ticagrelor
beyond the first month after PCI in an all-comers cohort with DES.
The risks and benefits of shortening DAPT to 3 months or even
shorter is another area with limited evidence. There are only two
randomized studies with a total of 5236 patients.105,106 Both studies
used the first-generation ZES that, due to its limited efficacy in sup-
pressing neointima formation, has been largely replaced by a newer
generation. Thus, in most cases with high bleeding risk, the decision
to shorten DAPT below 6 months needs to rely on circumstantial
evidence suggesting comparable safety of different stent types.
As outlined in section 4.1, there are no dedicated studies on the opti-
mal duration of DAPT after the application of drug-eluting balloons or
after implantation of a bioresorbable scaffold. It is also unclear whether,
early after placement of a bioresorbable stent, patients may benefit
from the more potent P2Y12 inhibition achieved by prasugrel or ticagre-
lor as compared with the current practice of clopidogrel administration.
5. Dual antiplatelet therapy and
cardiac surgery
5.1 Dual antiplatelet therapy in patients
treated with coronary artery bypass
surgery for stable coronary artery
disease
DAPT in ACS patients significantly reduces the risk of thrombotic com-
plications but increases the risk for both spontaneous and surgical
bleeding complications.20,23,40 The bleeding risk as well as the ischaemic
benefit are further increased if ticagrelor or prasugrel are used instead
of clopidogrel.20,23 Unlike for ACS, there is currently no evidence of a
survival benefit or a reduction of thromboembolic complications with
DAPT in patients with stable CAD undergoing CABG. However, there
is limited evidence suggesting that the use of DAPT in patients with sta-
ble CAD mitigates the risk of vein (but not arterial) graft occlusions.
5.2 Dual antiplatelet therapy in patients
treated with coronary artery bypass
surgery for acute coronary syndrome
Background: DAPT, as compared to aspirin monotherapy, has been pro-
ven to be beneficial in reducing ischaemic risk in ACS patients (Figure 5).
However, there is limited evidence in patients undergoing CABG as no
dedicated study exists. In the Clopidogrel in Unstable Angina to Prevent
Recurrent Events (CURE) trial, the outcome in the CABG
Figure 5 Algorithm for dual antiplatelet therapy (DAPT) in
patients with acute coronary syndrome undergoing coronary artery
bypass grafting. High bleeding risk is considered as an increased risk of
spontaneous bleeding during DAPT (e.g. PRECISE-DAPT score >_25).
Colour-coding refers to the ESC Classes of Recommendations
(green = Class I; yellow = IIa; orange = Class IIb). Treatments pre-
sented within the same line are sorted in alphabetic order, no prefer-
ential recommendation unless clearly stated otherwise.
1: if patient is not eligible for a treatment with prasugrel or
ticagrelor.
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subpopulation was consistent with the overall results of the study.147
Further support has been presented in two meta-analyses.148,149 In the
CABG substudies of the TRITON-TIMI 38 and the PLATO trials where,
respectively, prasugrel and ticagrelor were tested against clopidogrel in
combination with ASA, both newer P2Y12 inhibitors were more effec-
tive than clopidogrel in preventing fatal outcomes, with a higher risk for
bleeding in the former but not the latter trial.150,151
Continuation of DAPT until CABG increases the risk of excessive
perioperative bleeding, transfusions, and re-exploration for bleeding
as shown in RCTs,147,150,151 observational studies,152,153 and meta-
analyses.154,155 Therefore, it is recommended that the P2Y12 inhibitor
be discontinued whenever possible before elective CABG.156,157
Alternatively, elective operations may be postponed until the DAPT
treatment period is completed. In urgent cases, most often patients
with ACS, the risk of thrombotic episodes (stent thrombosis or MI)
while waiting for the effect of the P2Y12 inhibitor to cease must be
weighed against the risk of perioperative bleeding complications. In
extreme high-risk patients, e.g. those with recent DES implantation,
bridging therapy with cangrelor or a glycoprotein IIb/IIIa blocker may
be considered.156,157
P2Y12 inhibitors: The safe discontinuation interval varies between
the different P2Y12 inhibitors due to variations in platelet inhibitory
effect and pharmacodynamic and pharmacokinetic properties.158 For
clopidogrel, it was shown in the CABG substudy of the CURE trial
that discontinuation >_5 days before CABG did not increase the risk
of bleeding complications.147 For prasugrel, a longer time interval
(7 days) is recommended due to the longer offset time compared to
clopidogrel158 and the high incidence of CABG-related bleeding com-
plications reported in the CABG substudy of the TRITON-TIMI
38 trial.151 In CABG patients treated pre-operatively with ticagrelor,
5 days of discontinuation was initially recommended. This recom-
mendation was based on pharmacokinetic studies and clinical data
from patients with stable CAD.159 However, recent data from large
observational studies in CABG patients challenge this recommenda-
tion.152,153,160 In a Swedish nationwide study, CABG-related bleeding
complications in patients treated with ticagrelor or clopidogrel were
thoroughly investigated with respect to timing of P2Y12 inhibitor dis-
continuation.152 When either drug was discontinued according to
the instructions for use (>120 h before surgery), there was no significant
difference in the incidence of major bleeding complications between
ticagrelor- and clopidogrel-treated patients (9% vs. 12%; unadjusted OR
0.72, 95% CI 0.51–1.02; P = 0.065). Within the ticagrelor group, there
was no significant difference in major bleeding complications between
discontinuation 72–120 h or > 120 h before surgery (OR 0.93, 95% CI
0.53–1.64; P = 0.80), whereas discontinuation 0–72 h before surgery
was associated with a significantly higher rate of major bleeding com-
pared with both 72–120 h (OR 5.17, 95% CI 2.89–9.27; P < 0.0001)
and >120 h (OR 4.81, 95% CI 3.34–6.95; P < 0.0001). In contrast,
clopidogrel-treated patients had a higher incidence of major bleeding
complications when discontinued 72–120 h compared with >120 h
before surgery (OR 1.71, 95% CI 1.04–2.79; P = 0.033). Likewise, in the
clopidogrel group, discontinuation 0–72 h before surgery was associ-
ated with an increased incidence of major bleeding compared with
72–120 h (OR 1.67, 95% CI 1.02–2.73; P = 0.042) and >120 h (OR
2.85, 95% CI 1.98–4.10; P < 0.0001) (Web Figure 2, see Web
Addenda).152 Further support for using 3 days as the discontinuation
period in ticagrelor-treated patients comes from the PLATO trial,
where a discontinuation period of 24 - 72 h was recommended. In a sin-
gle institution Dutch registry encompassing 705 consecutive patients
who underwent isolated on-pump CABG, ticagrelor discontinuation
>72 h and clopidogrel discontinuation >120 h before surgery were not
associated with an increased risk of bleeding-related complications.153
Further evidence comes from a prospective, multicentre clinical
trial performed at 15 European centres, where discontinuation of
ticagrelor >2 days before surgery was not associated with increased
bleeding.160
It is unlikely that the optimal discontinuation period for any of
the P2Y12 inhibitors will ever be tested in an RCT. As mentioned
above, current guidelines recommend DAPT in all patients with
ACS, independent of revascularization strategy.34,161 This applies
to patients undergoing CABG and other cardiac surgical proce-
dures as well. Furthermore, the effect of DAPT or single antiplate-
let therapy after CABG has been compared in two meta-analyses
based on RCTs148 or a combination of RCTs and observational
studies.149 In the meta-analysis based on RCTs only (which
included 3717 ACS patients),148 there were no differences in all-
cause mortality in ASA þ clopidogrel vs. ASA only. Conversely,
all-cause mortality was significantly lower in ASA þ ticagrelor and
ASA þ prasugrel vs. ASA þ clopidogrel RCTs (RR 0.49, 95 % CI
0.33–0.71; P = 0.0002). There were no significant differences in
occurrence of MIs, strokes, composite outcomes, or major bleed-
ing (RR 1.31, 95 % CI 0.81–2.10, P = 0.27). The meta-analysis
based on both RCTs and observational studies149 included only
DAPT patients treated with clopidogrel. In this analysis, in-
hospital or 30-day mortality was lower with ASA þ clopidogrel
compared to ASA alone (RR 0.38, 95% CI 0.26–0.57; P < 0.001),
while the risk of angina or perioperative MI was comparable (RR
0.60, 95% CI 0.31–1.14; P = 0.12). Long-term mortality was not
reported. Patients treated with ASA þ clopidogrel demonstrated a
trend towards a higher incidence of major bleeding episodes as com-
pared to patients treated with ASA alone (RR 1.17, 95% CI 1.00–1.37;
P = 0.05). In both meta-analyses, there was large heterogeneity
between the included studies regarding study drug (clopidogrel/prasu-
grel/ticagrelor), study design, patient inclusion (ACS vs. stable CAD,
on-pump vs. off-pump surgery), study quality, and duration of follow-
up. The positive effect on survival appears to be more pronounced in
ACS patients and in patients treated with the second-generation P2Y12
inhibitors ticagrelor and prasugrel. However, re-institution of DAPT
after CABG may also slightly increase the risk of bleeding complica-
tions. Thus, it is recommended that DAPT is re-started as soon as it is
considered safe after CABG in ACS patients, with the exception of
those on anticoagulation. There is currently no scientific support for
triple antithrombotic treatment after CABG. Resuming DAPT early
after CABG is most likely of special importance in patients with recent
stent implantation, although strong evidence is lacking. The optimal
timing of resuming DAPT remains unclear, but 24 - 96 h after the oper-
ation in patients without recent stent implantation appears reasonable.
One reason for not starting DAPT immediately after the operation is
the considerable risk (30%) of atrial fibrillation (AF) during the first
post-operative days, which requires oral anticoagulation.162
Acetylsalicylic acid: A recent meta-analysis comparing pre-operative
ASA administration vs. no treatment or placebo in CABG patients
included 13 trials with a total of 2399 patients.163 The meta-analysis
showed that treatment with ASA reduced the risk of perioperative
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MI (OR 0.56, 95% CI 0.33–0.96) but not the mortality risk (OR 1.16,
95% CI 0.42–3.22), while post-operative bleeding, red blood cell
transfusions, and surgical re-explorations increased with ASA. The
authors pointed out that included studies had low methodological
quality. The recent Aspirin and Tranexamic Acid for Coronary
Artery Surgery (ATACAS) trial compared administration of ASA
(100 mg) on the day of surgery vs. placebo in CABG patients.164 The
study showed no significant effect of ASA treatment on perioperative
bleeding. On the other hand, ASA treatment did not reduce the inci-
dence of thrombotic events. It should be pointed out that the study
did not directly compare discontinuation vs. no discontinuation, since
the included patients were only eligible for the trial if they were not
using ASA pre-operatively or had stopped ASA at least 4 days before
surgery. Thus, the ATACAS study does not directly apply to the
ACS-CABG population and does not change current recommenda-
tions of maintaining ASA treatment during the perioperative period.
In a case-control study on 8641 CABG patients, those pre-treated
with ASA were less likely to experience in-hospital mortality in uni-
variate (OR 0.73, 95% CI 0.54–0.97) and multivariate (OR 0.55, 95%
CI 0.31–0.98) analysis relative to those not exposed to ASA.165 No
significant difference was seen in the amount of chest tube drainage,
transfusion of blood products, or need for re-exploration for bleed-
ing, between patients who were or were not exposed to ASA pre-
operatively.
Taken together, the evidence indicates that continuation of ASA
until cardiac surgery is associated with a moderately increased risk of
bleeding complications and a significant reduction in the risk of perio-
perative MI. If bleeding occurs during surgery, platelet transfusion has
been shown to effectively counteract ASA effects.166–168 This finding
further supports the possibility of continuing ASA throughout the
perisurgical period as ASA allows direct antiplatelet effect reversal if
clinically indicated. The increased risk of bleeding complications if
ASA and other antithrombotic drugs are not discontinued should be
weighed against the potentially increased risk of thrombotic compli-
cations during the pre-operative cessation period.
Platelet function testing: Besides the variance in platelet inhibitory
effects between different P2Y12 inhibitors, there is also a large individ-
ual variation in the magnitude and duration of the antiplatelet
effect.20,159,169–171 Because of the individual variation, the use of pla-
telet function tests may aid the optimization of the timing of surgical
procedures. However, platelet function tests could also be of value
to establish the grade of platelet inhibition in patients in whom the
time since discontinuation is unclear, e.g. in unconscious or confused
patients, and in patients with uncertain compliance to the treatment.
Treatment monitoring, using bedside tests, has been suggested as
an option for guiding interruption of treatment, rather than the use
of an arbitrary, specified period of time.156,157 Pre-operative ADP-
dependent platelet aggregation capacity predicts CABG-related
Dual antiplatelet therapy in patients treated with cardiac surgery with stable or unstable coronary artery disease
Recommendations Classa Levelb
It is recommended that the heart team estimates the individual bleeding and ischaemic risks, and guides the timing of
CABG as well as the antithrombotic management.
I C
In patients on aspirin who need to undergo non-emergent cardiac surgery, it is recommended to continue aspirin at a low
daily regimen throughout the perioperative period.
I C
In patients treated with DAPT after coronary stent implantation who subsequently undergo cardiac surgery, it is recom-
mended to resume P2Y12 inhibitor therapy post-operatively as soon as is deemed safe so that DAPT continues until the
recommended duration of therapy is completed.
I C
In patients with ACS (NSTE-ACS or STEMI) treated with DAPT, undergoing CABG, and not requiring long-term OAC ther-
apy, resumption of P2Y12 inhibitor therapy as soon as is deemed safe after surgery and continuation up to 12 months is
recommended.
I C
In patients on P2Y12 inhibitors who need to undergo non-emergent cardiac surgery, postponing surgery for at least 3
days after discontinuation of ticagrelor, at least 5 days after clopidogrel, and at least 7 days after prasugrel should be
considered.152,153,160
IIa B
In CABG patients with prior MI who are at high risk of severe bleeding (e.g. PRECISE-DAPT >_25), discontinuation of P2Y12
inhibitor therapy after 6 months should be considered.
IIa C
Platelet function testing may be considered to guide decisions on timing of cardiac surgery in patients who have recently
received P2Y12 inhibitors.
169,172–174 IIb B
In patients perceived to be at high ischaemic risk with prior MI and CABG, who have tolerated DAPT without a bleed-
ing complication, treatment with DAPT for longer than 12 and up to 36 months may be considered.
IIb C
ACS = acute coronary syndrome; CABG = coronary artery bypass graft surgery; DAPT = dual antiplatelet therapy; MI = myocardial infarction; NSTE-ACS = non-ST-elevation
acute coronary syndrome; OAC = oral anticoagulant; PRECISE-DAPT = PREdicting bleeding Complications in patients undergoing Stent implantation and subsEquent Dual Anti
Platelet Therapy; STEMI = ST-elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
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..bleeding complications in clopidogrel-172–174 and ticagrelor-
treated169 ACS patients, and a strategy based on pre-operative plate-
let function testing, to determine the timing of CABG in clopidogrel-
treated patients, led to a 50% shorter waiting time than that sug-
gested by a simple discontinuation time-based strategy.175 It should
be pointed out that the different platelet function tests and their
respective cut-off levels are not interchangeable.176 Taken together,
these results suggest that platelet function testing in ACS patients
referred for CABG is of potential value to guide the timing of surgery
in patients treated with P2Y12 inhibitors. However, randomized stud-
ies with clinically relevant endpoints are lacking.
5.3 Dual antiplatelet therapy for
prevention of graft occlusion
Two meta-analyses have compared graft patency in patients treated
with ASA alone or ASAþ clopidogrel after CABG.149,177 The studies
included in the meta-analyses comprised mainly patients with stable
CAD. In a meta-analysis by Deo et al,149 ASAþ clopidogrel was asso-
ciated with a significant reduction in saphenous vein graft occlusions
(RR 0.59, 95% CI 0.43–0.82; P = 0.02). In the meta-analysis by
Nocerino et al,177 DAPT was consistently associated with a reduced
occlusion rate (RR 0.63, 95% CI 0.46–0.86). DAPT proved useful in
preventing vein graft occlusion (RR 0.58, 95% CI 0.42–0.83), while no
clear effect was shown in arterial grafts (RR 0.85, 95% CI
0.39–1.85).177 Weak evidence indicates that DAPT may prevent graft
occlusion in patients undergoing off-pump CABG rather than on-
pump CABG.178 Given the low risk of thrombotic events after
CABG in stable patients, there is insufficient evidence to generally
recommend DAPT post-operatively to reduce vein graft occlusion in
this surgical patient subset.
5.4 Gaps in the evidence
There are several gaps in the evidence that pertain to the use
of DAPT in cardiac surgery. Clear gaps in evidence related to DAPT
in cardiac surgery patients include the question of whether DAPT
should be started after CABG in patients with stable CAD. Also, the
exact timing of post-operative DAPT restart remains unclear, and it
remains uncertain for how long the post-operative DAPT should last.
Further gaps in the evidence relate to: the optimal time point for dis-
continuation of the different P2Y12 inhibitors; the optimal use of pla-
telet function testing in patients awaiting cardiac surgery; how to
manage perioperative bleeding complications in cardiac surgery
patients caused by DAPT; and whether and how an incomplete
response or inadequate antiplatelet effect of aspirin after CABG
should be addressed.
6. Dual antiplatelet therapy for
patients with medically managed
acute coronary syndrome
The evidence for the use of DAPT in medically managed ACS
patients comes from the CHARISMA and CURE for
clopidogrel,40,95 TRILOGY for prasugrel,24 and PLATO and
PEGASUS for ticagrelor studies.20,29 There is no evidence in
favour of prasugrel treatment in patients with ACS who are medi-
cally managed, based on the negative results of the TRILOGY
study and the exclusion of this patient subset in the TRITON
study.23,24 The CURE study showed a consistent benefit in ACS
patients undergoing an average mean of 9 months DAPT in the
form of aspirin and clopidogrel as compared to 1-month therapy
in NSTE-ACS patients, irrespective of the final management strat-
egy, including or not including coronary revascularization.40 The
post-MI subset of patients in the CHARISMA trial derived signifi-
cant benefit with an NNT for benefit in the range of 100, which
came at the expense of higher major bleeding, with an NNT for
harm of 90.135 While the post-MI population represents only a
subset of those included in the CHARISMA study and the overall
results of the trial did not show benefit of DAPT as compared to
aspirin alone, it seems justifiable to give credit to this subanalysis
based on the consistency of results within multiple recent studies;
these studies showed that the long-term administration of an
intensified antiplatelet regimen beyond 1 year of treatment
reduced long-term ischaemic recurrences, even if at the cost of
higher bleeding.29,179
Patients medically managed in the PLATO trial derived consistent
benefit from ticagrelor 90 mg b.i.d. as compared to clopidogrel.
Overall mortality was also reduced in patients treated with ticagrelor
90 mg b.i.d.180
In the PEGASUS trial, 4271 patients had no prior coronary stent
implantation and they derived consistent benefits and risks from tica-
grelor vs. placebo on top of aspirin compared to patients with prior
stenting.
Multiple sources have shown that medically managed ACS patients
are less frequently treated with a DAPT regimen as compared to
patients who received PCI.181 Current evidence, especially for tica-
grelor, does not support this practice and clinicians should refrain
from tailoring the implementation and/or duration of a DAPT regi-
men depending on prior coronary stent implantation in the current
era of newer-generation DES (Figure 6).
A special population that warrants specific consideration com-
prises patients with established NSTE-ACS in whom no lumen
obstruction at coronary angiography is detected. No dedicated
study exists assessing the benefits and risks of DAPT in this patient
subset. However, a high prevalence of ruptured plaques has been
observed at intravascular imaging modalities in this population,182
suggesting that the benefits of DAPT in preventing recurrent MI
should not be withheld from these patients if the risk of bleeding
does not outweigh the anticipated benefit.
The evidence in support of the DAPT treatment option in
patients with STEMI conservatively managed or with prior lysis is
limited to 1 month of treatment.31,32 Yet, in consideration of the
fact that the majority of these patients would undergo invasive
management afterwards, and evidence that DAPT may be benefi-
cial irrespective of whether revascularization takes place, it is rea-
sonable to prolong DAPT further in these patients depending on
the bleeding risk.
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7. Dual antiplatelet therapy for
patients with indication for oral
anticoagulation
7.1 Risk stratification and strategies to
improve outcome after percutaneous
coronary intervention
Approximately 6–8% of patients undergoing PCI have an indication for
long-term oral anticoagulants (OACs) due to various conditions such
as AF, mechanical heart valves, or venous thromboembolism.
Compared with oral anticoagulation therapy alone, the addition of
DAPT to OAC therapy results in at least a two- to threefold increase
in bleeding complications.183–186 Therefore, these patients should be
considered at high risk of bleeding, and the indication for OAC should
be reassessed and treatment continued only if a compelling indication
exists {e.g. paroxysmal, persistent, or permanent AF with a CHA2DS2-
VASc [Cardiac failure, Hypertension, Age >_75 (2 points), Diabetes,
Stroke (2 points)–Vascular disease, Age 65–74, Sex category] score
>_1 in men, >_2 in women; mechanical heart valve; recent (i.e. 6 months)
or a history of recurrent deep venous thrombosis or pulmonary
embolism}. Conversely, every effort should be undertaken to imple-
ment strategies to minimize PCI-related complications in these patients
(Table 4). In particular, the duration of triple therapy should be limited
or omitted after hospital discharge (i.e. confined to the periprocedural
phase with aspirin being stopped thereafter), taking into account the
ischaemic (e.g. complexity of treated CAD, amount of disease left
untreated, technical considerations regarding stent implantation techni-
ques, and results) as well as the bleeding risks. While ischaemic risk
scores also predict bleeding outcomes in AF,187 suggesting consider-
able overlap among risk factors associated with ischaemic and bleeding
outcomes, multiple bleeding risk scores,188 including the HAS-BLED189
[Hypertension, Abnormal renal and liver function (1 point each),
Stroke, Bleeding history or predisposition, Labile INR, Elderly (>
65 years), Drugs and alcohol (1 point each)] score, have been shown
to outperform CHADS2 [Cardiac failure, Hypertension, Age, Diabetes,
Stroke (Doubled)] or CHA2DS2-VASc in predicting bleeding risk.
Importantly, HAS-BLED draws attention to the reversible bleeding
risk factors to be addressed by the responsible clinician during the fol-
low-up. Risk is not static and, particularly for bleeding, many risk factors
can be modified. Hence, a high risk of bleeding (e.g. HAS-BLED score
>_3) is not a reason to withhold OAC; instead, such patients should be
‘flagged-up’ for more careful review and follow-up.
More recently, the novel biomarker-based ABC [Age, Biomarkers
(GDF-15, cTnT-hs, and haemoglobin), and Clinical history (previous
bleeding)]190 bleeding risk score has been generated and validated in
a broad AF population treated with both vitamin K antagonist (VKA)
and non-vitamin K oral anticoagulants (NOACs), and has shown
superior prediction capability as compared to HAS-BLED. However,
similar to all other bleeding risk scores, none of these risk prediction
models developed for OAC patients has been prospectively tested in
the setting of prospective RCTs. Therefore, their value in improving
patient outcomes remains unclear.
A comprehensive list of all risk factors that have been associated
with greater bleeding risk has been previously published.162
In the absence of safety and efficacy data from RCTs [only 6% of
patients were treated at baseline with ticagrelor or prasugrel in the
Rivaroxaban and a dose-adjusted oral VKA treatment strategy in
Dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing medical therapy
management.
Recommendations Classa Levelb
In patients with ACS who are managed with medical therapy alone and treated with DAPT, it is recommended to con-
tinue P2Y12 inhibitor therapy (either ticagrelor or clopidogrel) for 12 months.
20,40 I A
Ticagrelor is recommended over clopidogrel, unless the bleeding risk outweighs the potential ischaemic benefit.20 I B
In patients with medically managed ACS who are at high risk of bleeding (e.g. PRECISE-DAPT >_25), DAPT for at least
1 month should be considered.
IIa C
In patients with prior MI at high ischaemic riskc who are managed with medical therapy alone and have tolerated DAPT
without a bleeding complication, treatment with DAPT in the form of ticagrelor 60 mg b.i.d. on top of aspirin for longer
than 12 months and up to 36 months may be considered.139
IIb B
In patients with prior MI not treated with coronary stent implantation, who have tolerated DAPT without a bleeding complica-
tion and who are not eligible for treatment with ticagrelor, continuation of clopidogrel on top of aspirin for longer than
12 months may be considered.
IIb C
Prasugrel is not recommended in medically managed ACS patients.24 III B
ACS = acute coronary syndrome; b.i.d. = bis in die; CrCl = creatinine clearance; DAPT = dual antiplatelet therapy; MI = myocardial infarction; PRECISE-DAPT = PREdicting
bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy.
aClass of recommendation.
bLevel of evidence.
cDefined as >_ 50 years of age, and one or more of the following additional high-risk features: age of 65 years or older, diabetes mellitus requiring medication, a second prior
spontaneous myocardial infarction, multivessel coronary artery disease, or chronic renal dysfunction, defined as an estimated creatinine clearance < 60 mL/min.
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subjects with atrial fibrillation who undergo percutaneous coronary
intervention (PIONEER AF-PCI) study191] and worrisome bleeding
signals in registries, the use of prasugrel or ticagrelor as part of triple
therapy should be avoided.192 Gastric protection with a PPI is recom-
mended. The dose intensity of OAC should be carefully monitored
with a target international normalized ratio (INR) in the lower part of
the recommended target range; in patients treated with NOACs, the
lowest effective tested dose for stroke prevention should be applied
and criteria for drug accumulation for each approved NOAC should
be carefully assessed. Lower NOAC regimens as compared to those
tested in approval studies are expected to decrease bleeding risk, but
the trade-off between bleeding and ischaemic (i.e. stroke prevention)
outcomes remains largely undefined. The PIONEER AF-PCI study191
(described in detail below) tested two lower rivaroxaban doses
(15 mg o.d. and 2.5 mg b.i.d.) as compared to the approved drug regi-
men in AF patients (20 mg q.d.). The Evaluation of Dual Therapy With
Dabigatran vs. Triple Therapy With Warfarin in Patients With AF
That Undergo a PCI With Stenting (REDUAL-PCI; NCT02164864)
will compare two dabigatran doses (150 mg b.i.d. and 110 mg b.i.d.) vs.
VKA and will provide additional insights with respect to the balance
between efficacy and safety for each one. Whether there are differ-
ences according to the type of OAC (NOACs vs. VKA) or stent plat-
form as well the duration of triple therapy is further discussed. These
considerations do not pertain to medically managed patients or to
patients eligible for CABG surgery in whom DAPT should be avoided
on top of OAC.
7.2 Duration of triple therapy
Cessation of aspirin after PCI while maintaining clopidogrel has been
evaluated in the What is the Optimal antiplatElet and anticoagulant
Table 4 Strategies to avoid bleeding complications in
patients treated with oral anticoagulant
ABC = Age, Biomarkers, Clinical history; CHA2DS2-VASc = Congestive heart
failure, Hypertension, Age >_75 years (doubled), Diabetes mellitus, prior Stroke
or transient ischaemic attack or thromboembolism (doubled), Vascular disease,
Age 65–74 years, Sex category; HAS-BLED = Hypertension, Abnormal renal/liver
function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/
alcohol concomitantly; NOAC = non-vitamin-K oral anticoagulant; INR = inter-
national normalized ratio; PCI = percutaneous coronary intervention; PPIs = pro-
ton pump inhibitors; VKA = vitamin K antagonist.
aApixaban 5 mg b.i.d or apixaban 2.5 mg b.i.d. if at least two of the following: age
>_80 years, body weight <_60 kg or serum creatinine level >_1.5 mg/dL (133 lmol/
L); dabigatran 110 mg b.i.d.; edoxaban 60 mg q.d. or edoxaban 30 mg q.d. if any of
the following: creatinine clearance (CrCl) of 30–50 mL/min, body weight <_60 kg,
concomitant use of verapamil or quinidine or dronedarone; rivaroxaban 20 mg
q.d. or rivaroxaban 15 mg q.d. if CrCl 30–49 mL/min.
Figure 6 Algorithm for dual antiplatelet therapy (DAPT) in
patients with acute coronary syndrome undergoing medical manage-
ment. High bleeding risk is considered as an increased risk of sponta-
neous bleeding during DAPT (e.g. PRECISE-DAPT score >_25).
Colour-coding refers to the ESC Classes of Recommendations
(green = Class I; yellow = IIa; orange = Class IIb). Treatments pre-
sented within the same line are sorted in alphabetic order, no prefer-
ential recommendation unless clearly stated otherwise.
1: if patient is not eligible for a treatment with ticagrelor
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.therapy in patients with OAC and coronary StenTing (WOEST) trial,
which randomized 573 patients (of whom 69% of patients had AF) to
dual therapy with OAC and clopidogrel (75 mg/day) or to triple ther-
apy with OAC, clopidogrel, and aspirin 80 mg/day.193 Treatment was
continued for 1 month after BMS placement and for 1 year after DES
placement (65% of patients). PCI was performed on VKA therapy in
half of the patients. The primary endpoint of any TIMI bleeds assessed
at 1-year follow-up was significantly reduced in the dual-therapy arm
(19.5% vs. 44.9%; HR 0.36, 95% CI 0.26–0.50; P < 0.001), while no sig-
nificant difference in major bleeding was observed. The rates of MI,
stroke, target vessel revascularization, or stent thrombosis did not
differ significantly, but all-cause mortality was lower in the dual-
therapy group (2.5% vs. 6.4%; P = 0.027) at 1 year.
More recently, the PIONEER AF-PCI study randomized 2124
patients with non-valvular AF who had undergone PCI with stenting
to receive, in a 1:1:1 ratio: low-dose rivaroxaban (15 mg o.d.) plus a
P2Y12 inhibitor (and no ASA) for 12 months; very-low-dose rivaroxa-
ban (2.5 mg b.i.d.) plus DAPT for 1, 6, or 12 months; or standard ther-
apy with a dose-adjusted VKA plus DAPT for 1, 6, or 12 months.191
The primary safety endpoint, consisting of TIMI clinically significant
bleeding, was lower in the two groups receiving rivaroxaban than in
the group receiving standard therapy [16.8% in patients treated with
rivaroxaban 15 mg, 18% in patients treated with rivaroxaban 2.5 mg,
and 26.7% in patients treated with triple therapy (HR 0.59, 95% CI
0.47–0.76; P < 0.001, and HR 0.63, 95% CI 0.50–0.80; P < 0.001,
respectively)]. It is worth mentioning that as many as 49% of patients
Figure 7 Algorithm for dual antiplatelet therapy (DAPT) in patients with an indication for oral anticoagulation undergoing percutaneous coronary
intervention (PCI). Colour-coding refers to the number of concomitant antithrombotic medication(s). Triple therapy denotes treatment with DAPT
plus oral anticoagulant (OAC). Dual therapy denotes treatment with a single antiplatelet agent (aspirin or clopidogrel) plus OAC.
ABC = age, biomarkers, clinical history; ACS = acute coronary syndrome; mo. = month(s); PCI = percutaneous coronary intervention.
1: Periprocedural administration of aspirin and clopidogrel during PCI is recommended irrespective of the treatment strategy.
2: High ischaemic risk is considered as an acute clinical presentation or anatomical/procedural features which might increase the risk for
myocardial infarction.
3: Bleeding risk can be estimated by HAS-BLED or ABC score.
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in both DAPT groups continued triple therapy for 12 months and no
difference in major bleeding or transfusion was observed across the
groups. Moreover, an INR range of 2–3 was recommended, instead
of 2–2.5, which may have inflated bleeding risk in the control group.
The rates of all-cause death, death from cardiovascular causes, MI, or
stroke were similar in the three groups.194 However, this study, simi-
lar to WOEST, was largely underpowered for the assessment of
meaningful differences in the incidence of relevant ischaemic events
such as stent thrombosis or stroke rates. Therefore, uncertainty
remains regarding the comparative performance of three tested
antithrombotic regimens in patients at high stroke and/or stent
thrombosis risk. Procedural characteristics of coronary intervention
have not been reported so far and patients with prior stroke were
excluded from participation. As a result, the balance of ischaemic and
bleeding risks of relatively short (i.e. 6 months or less) triple therapy
duration (possibly with NOAC instead of VKA) as compared to dou-
ble therapy consisting of clopidogrel and OAC remains unknown and
requires a patient-by-patient decision.
Dual therapy with clopidogrel and OAC after PCI remains an
appealing alternative to triple therapy given that patients exposed to
OAC are at high bleeding risk, but more data, especially on efficacy
and particularly in patients at high risk for stroke and/or recurrent
ACS, are needed. Cessation of clopidogrel while maintaining aspirin
has also been tested in the Triple Therapy in Patients on Oral
Anticoagulation After Drug Eluting Stent Implantation (ISAR-TRIPLE)
trial, where 614 patients (one-third with ACS) undergoing stenting
and requiring OAC were randomly assigned to receive either 6-
week or 6-month clopidogrel therapy in addition to aspirin and
VKA.195 The primary endpoint of death, MI, stent thrombosis, ischae-
mic stroke, or TIMI major bleeding at 9 months did not differ
between the 6-week and 6-month triple therapy (9.8% vs. 8.8%; HR
1.14, 95% CI 0.68–1.91; P = 0.63); the same was true for the com-
bined incidence of death, MI, stent thrombosis, and ischaemic stroke
(4.0% vs. 4.3%; HR 0.93, 95% CI 0.43–2.05; P = 0.87). Furthermore,
no difference in TIMI major bleeding (5.3% vs. 4.0%; HR 1.35, 95% CI
0.64–2.84; P = 0.44) was observed.
In all three studies, roughly one-third of patients presented with ACS.
There was no interaction between the duration of triple therapy and clini-
cal presentation (ACS vs. no ACS), which may reflect a real lack of
increased coronary ischaemic risk in these patients or a lack of power to
detect clinically meaningful differences in coronary ischaemic outcomes if
these patients undergo shorter duration of DAPT regimen (i.e. 1month195
or immediate discontinuation of aspirin after PCI191,193). The rate of bleed-
ing events peaked within the first 30 days of initiation of triple therapy
and was twice as high when compared with the rate of acute coronary
events including recurrent MI and stent thrombosis. These observa-
tions are consistent with the nationwide Danish registry of AF all-
comers with MI, where the 90-day bleeding risk was increased on triple
therapy compared with OAC plus a single antiplatelet agent (HR 1.47,
95% CI 1.04–2.08), with a consistent trend at 360 days (HR 1.36, 95%
CI 0.95–1.95), without differences in ischaemic events (HR 1.15, 95%
CI 0.95–1.40).196 The same registry suggests that warfarin plus clopi-
dogrel resulted in a non-significant reduction in major bleeds (HR 0.78,
95% CI 0.55–1.12) compared with triple therapy, with a non-significant
reduction in MI or coronary death (HR 0.69, 95% CI 0.55–1.12).197 For
these reasons, duration of triple therapy should be minimized depend-
ing on bleeding and ischaemic risks (Figure 7; Tables 5 and 6).
Dual antiplatelet therapy duration in patients with indi-
cation for oral anticoagulation
Recommendations Classa Levelb
It is recommended to administer periproce-
durally aspirin and clopidogrel in patients
undergoing coronary stent implantation.
I C
In patients treated with coronary stent implan-
tation, triple therapy with aspirin, clopidogrel,
and OAC should be considered for 1 month,
irrespective of the type of stent used.195
IIa B
Triple therapy with aspirin, clopidogrel, and
OAC for longer than 1 month and up to
6 months should be considered in patients
with high ischaemic risk due to ACS or
other anatomical/procedural characteristics
that outweigh the bleeding risk.195
IIa B
Dual therapy with clopidogrel 75 mg/day
and OAC should be considered as an alter-
native to 1-month triple antithrombotic
therapy in patients in whom the bleeding
risk outweighs the ischaemic risk.191,193
IIa A
Discontinuation of antiplatelet treatment in
patients treated with OAC should be con-
sidered at 12 months.198
IIa B
In patients with an indication for VKA in combi-
nation with aspirin and/or clopidogrel, the dose
intensity of VKA should be carefully regulated
with a target INR in the lower part of the rec-
ommended target range and a time in the ther-
apeutic range >65–70%.193,195
IIa B
When a NOAC is used in combination with
aspirin and/or clopidogrel, the lowest approved
dose effective for stroke prevention tested in
AF trials should be considered.c
IIa C
When rivaroxaban is used in combination with
aspirin and/or clopidogrel, rivaroxaban 15mg q.d.
may be used instead of rivaroxaban 20mg q.d.191
IIb B
The use of ticagrelor or prasugrel is not rec-
ommended as part of triple antithrombotic
therapy with aspirin and OAC.
III C
ACS = acute coronary syndrome; AF = atrial fibrillation; b.i.d. = bis in die; CrCl = creati-
nine clearance; INR = international normalized ratio; NOAC = non-vitamin K oral anti-
coagulant; OAC = oral anticoagulant; q.d. = quaque die; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cApixaban 5 mg b.i.d or apixaban 2.5 mg b.i.d. if at least two of the following: age
>_80 years, body weight <_60 kg or serum creatinine level >_1.5 mg/dL (133 lmol/
L); dabigatran 110 mg b.i.d.; edoxaban 60 mg q.d. or edoxaban 30 mg q.d. if any of
the following: CrCl of 30–50 mL/min, body weight <_60 kg, concomitant use of
verapamil, quinidine, or dronedarone; rivaroxaban 20 mg q.d. or rivaroxaban
15 mg q.d. if CrCl 30–49 mL/min.
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7.3 Cessation of all antiplatelet agents
Data on the timing of cessation of any antiplatelet agents in stented
patients requiring chronic OAC are scarce. In stabilized event-free
patients, discontinuation of any antiplatelet agent at 1 year after stent-
ing is encouraged in this patient population based on studies demon-
strating that OACs alone are superior to aspirin post-ACS, and OAC
þ aspirin may not be more protective but associated with excess
bleeding.198 Dual therapy with OAC and one antiplatelet agent
(aspirin or clopidogrel) may be considered beyond 1 year in patients
at very high risk of coronary events as defined in Table 534 and in
patients with mechanical prosthesis and atherosclerotic disease.
7.4 Type of anticoagulants
PIONEER AF-PCI is the only randomized study comparing VKAs and
NOACs in patients with AF undergoing PCI for ACS or for stable CAD
(i.e. patients who have an indication to receive DAPT).191 However, in
this study, two non-approved rivaroxaban regimens for AF patients
were tested and a low (i.e. 15 mg q.d.) or very low (i.e. 2.5 mg b.i.d.) rivar-
oxaban dose in combination with a single P2Y12 inhibitor or DAPT was
compared to VKA plus DAPT, respectively. The study was
underpowered for ischaemic endpoints. Therefore, no conclusion can
be made on the advantages and limitations of each OAC as compared
to others. However, there was an excess of stroke events in the 2.5 mg
b.i.d. rivaroxaban arm in combination with 6-month DAPT as compared
to VKA and 6-month DAPT (6 vs. 0 events; P = 0.02).
In the four phase III NOAC AF trials, no interactions were demon-
strated between treatment effect and outcome according to prior
coronary status (ACS vs. no ACS), and it is likely that the benefit of
NOAC over VKA is preserved in CAD patients with AF.199–202 At
least, this was the case among patients exposed to antiplatelet ther-
apy. There is no strong evidence for choosing one NOAC over
another. Dabigatran is the only NOAC that has been tested in a
phase III trial at reduced daily regimen (i.e. 110 mg b.i.d.) and for which
non-inferiority vs. warfarin was shown.199 Although lower doses of
other NOACs (i.e. apixaban 2.5 mg b.i.d. or edoxaban 30 mg o.d.)
might be considered to reduce bleeding risk, these dosages have
been evaluated only in a subset of patients in the phase III trials based
on prespecified dosing algorithms. Their benefit in stroke prevention
in patients with a normal renal function is uncertain. Three ongoing
large-scale outcome studies are evaluating combinations of NOACs
or VKAs with antiplatelet therapy in AF patients undergoing stent-
PCI (NCT02164864, NCT02415400, and NCT02866175). Various
dose regimens of NOAC, different types of P2Y12 inhibitors, and dif-
ferent exposure times are being evaluated.
7.5 Type of stent
The choice of newer-generation DES vs. BMS in patients requiring
long-term anticoagulation is no longer controversial. First, data from
the DAPT trial indicate a similar impact of prolonged DAPT adminis-
tration irrespective of stent type (BMS vs. DES),128 and the risk of
adverse events among patients with DAPT cessation and patients
undergoing non-cardiac surgery indicate no differences between
BMS and DES.17,129,203 Second, two randomized trials have demon-
strated the superiority of newer-generation DES over BMS in high
bleeding risk patients who cannot tolerate long-term exposure to
DAPT,130,204 such as those needing chronic OAC (section 2.2).
Altogether, both trials suggest that second-generation DES should
be the default choice in patients with high bleeding risk.
8. Elective non-cardiac surgery in
patients on dual antiplatelet
therapy
It is estimated that 5–25% of patients with coronary stents may
require non-cardiac surgery within 5 years after stent implantation.205
Management of patients on DAPT who are referred for surgical pro-
cedures involves consideration of: (1) the risk of stent thrombosis
(particularly if DAPT needs to be interrupted); (2) the consequences
of delaying the surgical procedure; and (3) the increased intra- and
periprocedural bleeding risk and possible consequences of such
bleeding if DAPT is continued.206–208 Given the complexity of these
considerations, a multidisciplinary approach—involving interven-
tional cardiologists, cardiologists, anaesthetists, haematologists, and
surgeons—is required to determine the patient’s risk for bleeding
and thrombosis and to choose the best management strategy.
Table 5 High-risk features of stent-driven recurrent
ischaemic events
Table 6 Unfavourable patient profile for a combina-
tion of oral anticoagulant and antiplatelet therapy
242 ESC Guidelines
Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/3/213/4095043
by E-Library Insel user
on 07 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Surgical interventions can be divided into low-risk, intermediate-risk,
and high-risk groups, with estimated 30-day cardiac event rates
for cardiac death or MI of < 1%, 1–5%, and >_5%, respectively.205,209
A practical classification of the bleeding risk associated with each type
of non-cardiac surgery has been recently proposed by the Stent
After Surgery group.210
In surgical procedures with low bleeding risk, every effort should be
taken not to discontinue DAPT perioperatively. In surgical procedures
with moderate bleeding risk, patients should be maintained on aspirin
while P2Y12 inhibitor therapy should be discontinued whenever possi-
ble. More challenging decision making is to be faced among patients on
DAPT who undergo high bleeding risk non-cardiac surgeries, including
vascular reconstructions, complex visceral procedures, neurosurgery,
and transbronchial operations.211–213 In these cases, particular atten-
tion should be paid to timely discontinuation of P2Y12 inhibitor therapy
to minimize the off-therapy period before surgical intervention.
Discontinuation before non-cardiac surgery: To reduce the risk of
bleeding and transfusion, it is recommended to postpone elective
non-cardiac surgery until completion of the full course of DAPT. In
most clinical situations, aspirin provides benefit that outweighs the
bleeding risk and should be continued.214,215 Possible exceptions to
this recommendation include intracranial procedures, transurethral
prostatectomy, intraocular procedures, and operations with
extremely high bleeding risk.157
A higher risk of ischaemic events in the case of non-cardiac surgery
has been reported after first-generation DES203 and a higher risk for
MACE has also been shown during the first weeks after non-cardiac
surgery in patients with implanted stents.203,216,217 Furthermore, sur-
gery per se, irrespective of the timing of DAPT discontinuation, is
associated with pro-inflammatory and pro-thrombotic effects,
thereby increasing the risk of coronary thrombosis at the level of the
stented vascular segment as well as throughout the coronary vascula-
ture.218,219 Therefore, in patients undergoing non-cardiac surgery
after recent ACS or stent implantation, the benefits of early surgery
for a specific pathology (e.g. malignant tumours or vascular aneurysm
repair) should be balanced against the risk of cardiovascular events
and the strategy should be discussed by a multidisciplinary team.
Prior recommendations with regard to duration of DAPT220,221
and the timing of non-cardiac surgery207,222 in patients treated with
DES were based on observations of those treated with first-
generation DES. Compared with first-generation DES, currently used
newer-generation DES are associated with a lower risk of stent
thrombosis and appear to require a shorter minimum duration of
DAPT.100,103,104,223–225 Furthermore, in the PARIS registry, interrup-
tion of DAPT grounded on physician judgment in patients undergoing
surgery at any time point after PCI was not associated with an
increased risk of MACE.17
In the absence of a surgical control group, it remains challenging to
identify a clear time frame after ACS or coronary stenting where
there is no additional risk or the risk is acceptably low for patients to
undergo surgery. Therefore, almost all registries have attempted to
identify such landmarks by looking at the time course of the surgical
ischaemic risk over time in order to identify when it levels off and
remains stable thereafter following an ACS or stent implantation pro-
cedure.17 By doing so, many registries have reported that surgery-
associated risk in DES-PCI-treated patients reaches a stable level
after 3–6 months.17,214,215 However, without a surgical control
group, these findings are potentially influenced by the type and
urgency of the surgical procedures. To overcome this limitation, two
large matched cohorts of patients undergoing surgery were recently
reported. Using Danish population-based registries and individual-
based record linkage of Danish registries, 4303 DES-PCI-treated
patients who underwent a surgical procedure within 12 months were
identified and were compared with a control group of patients with-
out established stable CAD undergoing similar surgical procedures (n
= 20 232).226 This evaluation of the comparative risk associated with
surgery in DES-PCI-treated patients vs. patients without known sta-
ble CAD revealed an increased overall risk for MI and cardiac death
in the patients with previous DES-PCI, owing to higher MI rates but
similar mortality risk.226 However, this difference was highly time-
dependent and limited to the first month after DES-PCI.226 These
data suggest that surgery, if possible, should be delayed for at least
1 month after DES-PCI. Data for patients with coronary stents
implanted in a Veterans’ Administration (VA) hospital from 2000 to
2010 were also recently matched with VA Surgical Quality
Improvement Program data to identify non-cardiac surgery within
24 months of stent placement.227 Each patient with a stent(s) was
matched with two surgical patients without stents on surgical charac-
teristics and cardiac risk factors. The two groups had similar risk of
adverse cardiac events during 2 years of follow-up. However, patients
with stents had a higher risk of adverse cardiac events within the
30-day post-operative period.227 The incremental risk did not vary by
stent type.227 In both studies, roughly 50% of patients underwent
stenting because of ACS and no incremental risk was observed in this
higher risk population as compared to stable CAD patients.
Therefore, a minimum of 1 month of DAPT should be considered,
independently of the type of implanted stent (i.e. BMS or newer-gen-
eration DES), in cases when surgery cannot be delayed for a longer
period; however, such surgical procedures should be performed in
hospitals where catheterization laboratories are available 24/7, so as
to treat patients immediately in case of perioperative thrombotic
events (Figure 8). In patients at high ischaemic risk due to ACS pre-
sentation or complex coronary revascularization procedure, delaying
surgery up to 6 months after index ACS or PCI may be reasonable as
an additional safeguard to minimize the risk of perisurgical MI, and
based on unmatched retrospective registry data if the risks of further
delaying surgery are acceptable.
In patients needing surgery within a few days, it was previously rec-
ommended to withhold clopidogrel and ticagrelor for 5 days and pra-
sugrel for 7 days prior to surgery unless there is a high risk of
thrombosis.228 However, emerging evidence, which is extensively
discussed in Chapter 5, challenges such a long discontinuation period
for ticagrelor before a safe surgical procedure can be undertaken
(Figure 9).152,153
Although these data refer to patients undergoing cardiac surgery,
it is rational to extend these findings to the non-cardiac surgery popu-
lation, given the same offset kinetics and principally lower risk of
bleeding in non-cardiac surgeries relative to cardiac surgery proce-
dures (Figure 9). In cases where the consequences of even minor
bleeding would be unacceptable (e.g. spinal surgery or other neuro-
surgical procedures) or the bleeding risk largely outweighs the ischae-
mic risk (e.g. a medium- to high-risk surgical bleeding procedure is
undertaken 6 months or more after single stent implantation for sta-
ble CAD indication), P2Y12 inhibitors may be discontinued for a
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longer duration of time to ensure no residual platelet inhibition at the
time of planned surgery. For patients with a very high risk of stent
thrombosis, bridging therapy with intravenous, reversible glycopro-
tein inhibitors, such as eptifibatide or tirofiban,229 may be considered.
Cangrelor, a reversible intravenous P2Y12 inhibitor, has been shown
to provide effective platelet inhibition230 and is an appealing alterna-
tive to glycoprotein IIb/IIIa inhibitors,231 given the well-known role of
P2Y12 inhibition in preventing stent thrombosis and the quicker offset
of action as compared to tirofiban or eptifibatide. Concomitant
parenteral anticoagulation therapy in conjunction with cangrelor or
reversible glycoprotein inhibitors is not recommended to minimize
bleeding risk while awaiting surgical procedures.
Restart after surgery: If P2Y12 inhibitor therapy has been stopped
before a surgical procedure, therapy should be restarted as soon
as possible (within 48 h), given the substantial thrombotic hazard
associated with lack of platelet inhibition early after surgery in
patients with recent stent implantation and/or an ACS episode
(Figure 9).232,233
The time for restarting P2Y12 inhibitors after surgery should ulti-
mately be determined via a multidisciplinary discussion before sur-
gery and traced in the patient file.
Dual antiplatelet therapy in patients undergoing elec-
tive non-cardiac surgery
Recommendations Classa Levelb
It is recommended to continue aspirin peri-
operatively if the bleeding risk allows, and to
resume the recommended
antiplatelet therapy as soon as possible
post-operatively.232–236
I B
After coronary stent implantation, elective
surgery requiring discontinuation of the
P2Y12 inhibitor should be considered after
1 month, irrespective of the stent type, if
aspirin can be maintained throughout the
perioperative period.227
IIa B
Discontinuation of P2Y12 inhibitors should
be considered at least 3 days before surgery
for ticagrelor, at least 5 days for
clopidogrel, and at least 7 days for
prasugrel.152,153,160
IIa B
A multidisciplinary expert team should be
considered for pre-operative evaluation of
patients with an indication for DAPT before
elective surgery.
IIa C
In patients with recent MI or other high
ischaemic risk featuresc requiring DAPT,
elective surgery may be postponed for up
to 6 months.17,214,215,234
IIb C
If both oral antiplatelet agents have to be
discontinued perioperatively, a bridging
strategy with intravenous antiplatelet agents
may be considered, especially if surgery has
to be performed within 1 month after stent
implantation.229,237–239
IIb C
It is not recommended to discontinue
DAPT within the first month of treatment
in patients undergoing elective non-cardiac
surgery.203
III B
DAPT = dual antiplatelet therapy; MI = myocardial infarction.
aClass of recommendation.
bLevel of evidence.
cHigh ischaemic risk features are provided in Table 5.
Figure 8 Timing for elective non-cardiac surgery in patients
treated with dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI). Colour-coding refers to the ESC
Classes of Recommendations (green = Class I; yellow = IIa; orange
= Class IIb).
ACS = acute coronary syndromes.
1Availability of H24 cath-lab service in place is suggested in
case of major surgery within 6 months after PCI.
2High ischaemic risk features are presented in Table 5.
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..9. Gender consideration and
special populations
9.1 Gender specificities
There is no convincing evidence for a gender-related difference in the
efficacy and safety of currently available DAPT type or duration across
studies. No single trial or pooled analysis of investigations assessing a
shorter than 1 year vs. at least 1 year DAPT duration has shown heter-
ogeneous findings across genders.26,112,240,241 In the DAPT trial, there
was a borderline quantitative interaction suggesting a lower relative
treatment benefit for stent thrombosis reduction with prolonged
DAPT in female as compared to male patients (Pint =0.04).
26
However, no such signal was apparent for MACCE (Pint = 0.46) or
bleeding (Pint = 0.40) endpoints. Within the PEGASUS trial, there was
no signal suggesting heterogeneity across the primary study endpoint
with respect to gender (Pint = 0.84).
29 On the other hand, there was a
positive quantitative interaction (Pint = 0.03) suggesting that female
patients may derive a relatively greater treatment benefit with respect
to stroke prevention from prolonged treatment with aspirin and tica-
grelor as compared to aspirin alone. However, no such signal was evi-
dent for cardiovascular death, MI, or safety endpoints.
9.2 Diabetes mellitus
Patients with diabetes mellitus presenting with both stable and unsta-
ble CAD carry a worse prognosis in terms of short- and long-term
risks of fatal and non-fatal ischaemic events, with enhanced platelet
hyperactivity playing a putative causal role. In the CURE trial, patients
with diabetes derived a similar treatment benefit from the addition of
clopidogrel on top of aspirin as compared to patients without.40 No
signal for greater treatment benefit was apparent in TRITON-TIMI
38 in patients with diabetes as compared to those without with
respect to the study primary endpoint, and a consistent lack of heter-
ogeneity signal with respect to diabetes mellitus was observed in the
PLATO trial.20,23 Hence, there is no convincing evidence that the
presence of diabetes should affect decision making with respect to
the choice of P2Y12 inhibitors.
As it related to DAPT duration, the DAPT study found a slightly
lower relative risk reduction for MI endpoint in patients with diabetes
as compared to those without diabetes (Pint = 0.02).
242 However,
there was no signal for heterogeneity with respect to the concomitant
presence of diabetes mellitus across all other ischaemic or safety end-
points. Finally, no difference with respect to the presence or absence
of diabetes was observed for the primary efficacy endpoint in the
PEGASUS study (Pint = 0.99).
145 Altogether, current evidence suggests
that diabetes mellitus should not be the only appraised patient-specific
feature when deciding upon the type or duration of DAPT.
9.3 Lower-extremities artery disease
Patients with LEAD are at heightened risk of ischaemic complications
and mortality. The combination of symptomatic LEAD and CAD is
associated with further heightened ischaemic risk beyond that associ-
ated with symptomatic disease in either vascular bed alone.243 In 3096
patients with LEAD included in the CHARISMA trial, DAPT was asso-
ciated with a lower rate of MI and hospitalization for ischaemic events
but not the overall composite primary endpoint. There was no differ-
ence between the groups in moderate, severe, or fatal bleeding, but
there was an increase in minor bleeding in the DAPT group.244 The
PEGASUS investigators recently examined a subgroup of 1143 patients
with LEAD and found that patients with prior MI with LEAD had a 60%
increased risk of MACE relative to patients without LEAD, even after
adjusting for differences in baseline characteristics.140 This increased
ischaemic risk translated into a robust absolute risk reduction of 5.2%
at 3 years with ticagrelor 60 mg b.i.d. compared with placebo. In the set-
ting of this robust ischaemic risk reduction, there were significant
reductions in cardiovascular and all-cause mortality. Treatment with
ticagrelor vs. placebo reduced the risk of adverse limb events in addi-
tion to the benefits observed for MACE and mortality. Reductions in
acute limb ischaemia have also been shown with other antiplatelet
Figure 9 Minimal discontinuation and re-implementation time frames of dual antiplatelet therapy (DAPT) for patients undergoing elective surgery
OAC = oral anticoagulant.
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Figure 10 Practical recommendations for the management of bleeding in patients treated with dual antiplatelet therapy with or without concomi-
tant oral anticoagulation. Practical recommendations for the management of bleeding in patients treated with dual antiplatelet therapy with or with-
out concomitant oral anticoagulation. Blue boxes refer to management of antiplatelet therapy. Dark-red boxes refer to the management of oral
anticoagulation. Light-green boxes refer to general recommendation for patients’ safety.
ACS = acute coronary syndrome; CHA2DS2-VASc= cardiac failure, hypertension, age >_75 (2 points), diabetes, stroke (2 points)–vascu-
lar disease, age 65–74, sex category; DAPT = dual antiplatelet therapy; GI = gastrointestinal; HB = haemoglobin; INR = international
normalized ratio; i.v. = intravenous; OAC = oral anticoagulant; NOAC = non-vitamin-K antagonist; PPI = proton pump inhibitor; RBC
= red blood cell; SAPT = single antiplatelet therapy.
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..agents, such as vorapaxar, demonstrating that this morbidity is modifi-
able with potent and prolonged antithrombotic strategies.245 In the all-
comer PRODIGY trial, 246 (12.5%) patients were included with symp-
tomatic LEAD. LEAD status was associated with a higher risk of death
and ischaemic events (HR 2.80, 95% CI 2.05–3.83; P < 0.001).246
Prolonged vs. short DAPT conveyed a lower risk of the primary effi-
cacy endpoint in LEAD patients (16.1% vs. 27.3%; HR 0.54, 95% CI
0.31–0.95; P = 0.03) but not in patients without LEAD (9.3% vs. 7.4%;
HR 1.28, 95% CI 0.92–1.77; P = 0.14), with positive interaction (P =
0.01). The risk of definite or probable stent thrombosis as well as
Figure 10 Continued
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..overall mortality was significantly lower in LEAD patients treated with
prolonged DAPT as compared with those receiving short DAPT.
9.4 Complex percutaneous coronary
intervention
While high PCI complexity intuitively represents a driver for favouring
a prolonged over a shortened DAPT duration, the evidence regarding
optimal DAPT duration based on complexity of intervention is limited.
In a patient-level meta-analysis from six RCTs investigating DAPT
durations after coronary stenting, including 9577 patients, complex
PCI was defined as the composite of at least three stents implanted, at
least three lesions treated, bifurcation with two stents implanted, total
stent length >60 mm, and chronic total occlusion as target lesion.247
Patients who underwent complex PCI had a two-fold increase of
MACE (5.0% vs. 2.5%; P = 0.001). Long- and short-DAPT were
defined as a DAPT duration >_12 months and <_6 months, respectively.
Compared with short-DAPT, long-DAPT was associated with a signif-
icant reduction in MACE in the complex PCI group (4.0% vs. 6.0%;
adjusted HR 0.56, 95% CI 0.35–0.89) vs. the non-complex PCI group
(2.5% vs. 2.6%; adjusted HR 1.01, 95% CI 0.75–1.35; Pint = 0.01). The
magnitude of the reduction in MACE with long-DAPT increased pro-
gressively as the degree of procedural complexity was greater. Long-
DAPT was overall associated with increased risk of major bleeding,
which was uniform in magnitude between groups (Pint = 0.15).
9.5 Dual antiplatelet therapy decision
making in patients with stent thrombosis
Patients presenting with stent thrombosis represent a challenging
patient population in whom no randomized clinical evidence is available
to guide decision making. Observational studies have shown that the
risk of stent thrombosis recurrence after the first episode of stent
thrombosis is worrisome. Armstrong et al reported on a combined ret-
rospective and prospective observational California registry of angio-
graphic definite stent thrombosis at five academic hospitals from 2005
to 2013.248 The entry criterion was the occurrence of a definite stent
thrombosis, which was observed in 221 patients overall out of an
unknown number of patients at risk. With the important caveat of not
knowing for each stent type the exact timing of the first stent thrombo-
sis event after the index procedure, 104 (47%) patients had received a
first generation DES, 51 (23%) a BMS, and 19 (9%) a second generation
DES. After a median follow-up of 3.3 years, 29 patients developed defi-
nite or probable recurrent stent thrombosis, while 19 presented angio-
graphic definite recurrent stent thrombosis. The cumulative hazard of
definite or probable recurrent stent thrombosis was 16% at 1 year and
24% at 5 years. The cumulative hazard of angiographic definite recurrent
stent thrombosis was 11% at 1 year and 20% at 5 years. Taken together,
these findings confirm the high risk of stent thrombosis recurrence after
the first stent thrombosis. An additional piece of information, which is
conveyed by this important analysis, is that the risk of recurrence is high-
est in the first few months after the first event and that it does not abate
entirely over time. Both prasugrel and ticagrelor have been shown to
be associated with a significant reduction of definite and definite or
probable stent thrombosis as compared to clopidogrel.20,23 Moreover,
both studies indicated that the number of recurrent events is also signifi-
cantly decreased by treatment with ticagrelor or prasugrel as compared
to clopidogrel. Hence, the use of clopidogrel after stent thrombosis
cannot be regarded as an effective treatment option. Considering the
long-term risk of recurrence after first stent thrombosis, it may be rea-
sonable to make every effort to maintain DAPT for a very long-term
period in this highly selected high-risk patient population, if tolerated.
9.6 Patients who develop bleeding while
on treatment
Patients who develop bleeding complications while on DAPT repre-
sent a challenging patient population for whom no guidance from
RCTs is available.
The decision to withhold or continue DAPT in this setting largely
depends on ischaemic (e.g. indication for DAPT and time from last
stent insertion, if any, to bleeding) vs. recurrent/prolonged bleeding
risks. A practical flow chart in order to manage this challenging popu-
lation is provided in Figure 10 and additional information on practical
management can be found elsewhere.249 As bleeding is an independ-
ent predictor of recurrent bleeding,250 type, dose, and duration of
DAPT should be reassessed in this setting.
Gender considerations and special populations
Recommendations Classa Levelb
Similar type and duration of DAPT are rec-
ommended in male and female
patients.26,240
I A
It is recommended to reassess the type,
dose, and duration of DAPT in patients with
actionable bleeding complications while on
treatment.
I C
Similar type and duration of DAPT should
be considered in patients with and without
diabetes mellitus.145,242
IIa B
Prolonged (i.e. >12 monthsc) DAPT dura-
tion should be considered in patients with
prior stent thrombosis, especially in the
absence of correctable causes (e.g. lack of
adherence or correctable mechanical stent-
related issues).
IIa C
Prolonged (i.e. >12 months) DAPT duration
may be considered in CAD patients with
LEAD.140,246
IIb B
Prolonged (i.e. >6 months) DAPT durationd
may be considered in patients who under-
went complex PCI.247
IIb B
CAD = coronary artery disease; DAPT = dual antiplatelet therapy; LEAD =
lower-extremities artery disease; PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
cPossibly for as long as can be tolerated.
dComplex PCI defined as the composite of at least three stents implanted, at
least three lesions treated, bifurcation with two stents implanted, total stent
length >60 mm, and chronic total occlusion as target lesion.
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..10. Key messages
(1) Benefits and risks of DAPT: DAPT reduces the risk of stent throm-
bosis across the entire spectrum of events, from acute to very late
occurrences. However, treatment with DAPT beyond 1 year after
MI, or after PCI, exerts the majority of its benefit by reducing the
rate of spontaneous MI. The risk of bleeding in patients on DAPT is
proportionally related to its duration both within and beyond
1 year of treatment duration. Since the benefits of prolonged
DAPT, especially for mortality endpoints, appear highly dependent
on prior cardiovascular history (such as prior ACS/MI vs. stable
CAD), and prediction models to estimate on-DAPT bleeding risk
have been developed, an individualized approach based on ischae-
mic vs. bleeding risk assessment is warranted.
(2) Bleeding mitigation strategy: Every effort should be pursued to mit-
igate the risk of bleeding complications while the patient is on
DAPT, including access site selection, modulation of modifiable
risk factors for bleeding, low dose aspirin, low dose of P2Y12
inhibitor as appropriate, and routine use of PPI.
(3) P2Y12 inhibitor selection: Clopidogrel is considered the default
P2Y12 inhibitor in patients with stable CAD treated with PCI,
those with indication to concomitant oral anticoagulation, as well
as in ACS patients in whom ticagrelor or prasugrel are contraindi-
cated. Ticagrelor or prasugrel is recommended in ACS patients
unless drug-specific contraindications exist.
(4) Timing of P2Y12 inhibitor initiation: The timing of initiation of a
P2Y12 inhibitor is both drug- (i.e. ticagrelor or clopidogrel vs. pra-
sugrel) and disease-specific (i.e. SCAD vs. ACS and type thereof).
(5) Stable CAD patients treated with PCI: Irrespective of the type of met-
allic stent implanted, the duration of DAPT is 1–6month(s) depending
on the bleeding risk. For patients in whom the ischaemic risk prevails
over the risk of bleeding, a longer DAPT duration may be considered.
(6) Metallic stent type and DAPT duration: The need for a short
DAPT regimen should no longer justify the use of BMS instead of
newer-generation DES. DAPT duration in each individual patient
should be guided by an individualized approach based on ischaemic
vs. bleeding risk assessment and not by the stent type.
(7) Stable CAD patients treated with CABG: There is insufficient data
to recommend DAPT in this patient population.
(8) ACS patients: Irrespective of the final revascularization strategy
(e.g. medical therapy, PCI, or CABG), the default DAPT duration
in these patients is 12 months. Six-month therapy duration should
be considered in high bleeding risk patients, whereas >12-month
therapy may be considered in ACS patients who have tolerated
DAPT without a bleeding complication.
(9) Patients with indication for oral anticoagulation: Compared with
OAC therapy alone, the addition of DAPT to OAC therapy results
in at least a two- to three-fold increase in bleeding complications.
Therefore, these patients should be considered at high risk of
bleeding and the indication for OAC should be reassessed and
treatment continued only if a compelling indication exists.
The duration of triple therapy should be limited up to a maximum
of 6 months or omitted after hospital discharge, taking into account
the ischaemic (e.g. complexity of treated CAD, amount of disease
left untreated, technical considerations regarding stent implantation
techniques, and results) as well as the bleeding risk. The use of tica-
grelor or prasugrel in this setting is not recommended.
(10) Patients undergoing elective non-cardiac surgery after coronary stent
implantation: A multidisciplinary expert team should be considered
for pre-operative evaluation of patients with an indication for DAPT
before elective surgery. Scheduled surgery requiring discontinuation
of the P2Y12 inhibitor should be considered after at least 1 month,
irrespective of the stent type, if aspirin can be maintained throughout
the perioperative period. If both oral antiplatelet agents have to be
discontinued perioperatively, a bridging strategy with cangrelor, tirofi-
ban, or eptifibatide may be considered, especially if surgery has to be
performed within 1 month after stent implantation.
(11) Gender consideration and special populations: Similar type and dura-
tion of DAPT are recommended in male and female patients, as well
as in patients with and without diabetes mellitus. Patients with prior
stent thrombosis, especially in the absence of correctable causes,
should receive prolonged DAPT. A prolonged DAPT regimen may
also be considered in patients with LEAD or who have undergone
complex PCI. It is recommended to reassess the type, dose, and dura-
tion of DAPT in patients with actionable bleeding complications while
on treatment. In patients with active bleeding while on DAPT, the
decision to stop both antiplatelet agents, especially if shortly after PCI,
should be taken only if the bleeding is life-threatening and the source
has not been or cannot be treated. In such a rare case scenario, the
patient should be transferred to a primary PCI facility centre.
11. Evidenced-based ‘to do and
not to do’ messages
Recommendations that are class I or III with a level of evidence A or B
Recommendations on P2Y12 inhibitor selection and timing Class
a Levelb
In patients with ACS, ticagrelor (180 mg loading dose, 90 mg b.i.d.) on top of aspirin is recommended, regardless of initial
treatment strategy, including patients pre-treated with clopidogrel (which should be discontinued when ticagrelor is com-
menced) unless there are contraindications.c
I B
In patients with ACS undergoing PCI, prasugrel (60 mg loading dose, 10mg o.d.) on top of aspirin is recommended for P2Y12 inhibi-
tor-naı̈ve patients with NSTE-ACS or initially conservatively managed STEMI if indication for PCI is established, or in STEMI patients
undergoing immediate coronary catheterization unless there is a high risk of life-threatening bleeding or other contraindications.c
I B
Continued
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Pre-treatment with a P2Y12 inhibitor is generally recommended in patients in whom coronary anatomy is known and the
decision to proceed to PCI is made, as well as in patients with STEMI.
I A
Clopidogrel (600 mg loading dose, 75 mg o.d.) on top of aspirin is recommended in stable CAD patients undergoing
coronary stent implantation and in ACS patients who cannot receive ticagrelor or prasugrel, including those with prior
intracranial bleeding or indication for OAC.
I A
Clopidogrel (300 mg loading dose in patients aged <_75, 75 mg o.d.) is recommended on top of aspirin in STEMI patients
receiving thrombolysis.
I A
In NSTE-ACS patients in whom coronary anatomy is not known, it is not recommended to administer prasugrel. III B
Measures to minimize bleeding while on dual antiplatelet therapy
Radial over femoral access is recommended for coronary angiography and PCI if performed by an expert radial operator. I A
In patients treated with DAPT, a daily aspirin dose of 75 - 100 mg is recommended. I A
A PPI in combination with DAPT is recommended.d I B
Routine platelet function testing to adjust antiplatelet therapy before or after elective stenting is not recommended. III A
Switching between oral P2Y12 inhibitors
In patients with ACS who were previously exposed to clopidogrel, switching from clopidogrel to ticagrelor is
recommended early after hospital admission at a loading dose of 180 mg irrespective of timing and loading dose of
clopidogrel, unless contraindications to ticagrelor exist.c
I B
Dual antiplatelet therapy duration in patients with acute coronary syndrome treated with percutaneous coronary intervention
In patients with ACS treated with coronary stent implantation, DAPT with a P2Y12 inhibitor on top of aspirin is
recommended for 12 months unless there are contraindications such as excessive risk of bleeding (e.g.
PRECISE-DAPT >_25).
I A
Dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing medical therapy management
In patients with ACS who are managed with medical therapy alone and treated with DAPT, it is recommended to continue
P2Y12 inhibitor therapy (either ticagrelor or clopidogrel) for 12 months.
I A
Ticagrelor is recommended over clopidogrel, unless the bleeding risk outweighs the potential ischaemic benefit. I B
Prasugrel is not recommended in medically managed ACS patients. III B
Dual antiplatelet therapy in patients undergoing elective cardiac and non-cardiac surgery
It is recommended to continue aspirin perioperatively if the bleeding risk allows, and to resume the recommended
antiplatelet therapy as soon as possible post-operatively.
I B
It is not recommended to discontinue DAPT within the first month of treatment in patients undergoing elective non-cardiac
surgery.
III B
Gender considerations
Similar type and duration of DAPT are recommended in male and female patients. I A
ACS = acute coronary syndrome; CAD = coronary artery disease; DAPT = dual antiplatelet therapy; NSTE-ACS = non-ST elevation acute coronary syndrome; OAC = oral
anticoagulant; PCI = percutaneous coronary intervention; PPI = proton pump inhibitor; PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent
implantation and subsEquent Dual Anti Platelet Therapy; STEMI = ST-elevation myocardial infarction; TIA = transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
cContraindications for ticagrelor: previous intracranial haemorrhage or ongoing bleeds. Contraindications for prasugrel: previous intracranial haemorrhage, previous ischaemic
stroke or TIA, or ongoing bleeds; prasugrel is not recommended for patients >_75 years of age or with a body weight <60 kg.
dWhile the evidence that a PPI does not increase the risk of cardiovascular events was generated with omeprazole, based on drug–drug interaction studies, omeprazole and
esomeprazole would appear to have the highest propensity for clinically relevant interactions, while pantoprazole and rabeprazole have the lowest.
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..12. Web addenda and Clinical
Cases companion document
All Web figures, Web tables, and the Clinical Cases companion docu-
ment are available at the European Heart Journal online and also via
the ESC Web site at: www.escardio.org/guidelines
13. Appendix
ESC Committee for Practice Guidelines (CPG): Stephan
Windecker (Chairperson) (Switzerland), Victor Aboyans (France),
Stefan Agewall (Norway), Emanuele Barbato (Italy), Héctor Bueno
(Spain), Antonio Coca (Spain), Jean-Philippe Collet (France), Ioan
Mircea Coman (Romania), Veronica Dean (France), Victoria Delgado
(The Netherlands), Donna Fitzsimons (UK), Oliver Gaemperli
(Switzerland), Gerhard Hindricks (Germany), Bernard Iung (France),
Peter Jüni (Canada), Hugo A. Katus (Germany), Juhani Knuuti
(Finland), Patrizio Lancellotti (Belgium), Christophe Leclercq
(France), Theresa McDonagh (UK), Massimo Francesco Piepoli
(Italy), Piotr Ponikowski (Poland), Dimitrios J. Richter (Greece),
Marco Roffi (Switzerland), Evgeny Shlyakhto (Russia), Iain A. Simpson
(UK), and Jose Luis Zamorano (Spain)
ESC National Cardiac Societies actively involved in the
review process of the 2017 ESC focused update on dual
antiplatelet therapy in coronary artery disease in collabora-
tion with EACTS:
Austria: Austrian Society of Cardiology, Franz Xaver Roithinger;
Azerbaijan: Azerbaijan Society of Cardiology, Farid Aliyev;
Belarus: Belorussian Scientific Society of Cardiologists, Valeriy
Stelmashok; Belgium: Belgian Society of Cardiology, Walter
Desmet; Bulgaria: Bulgarian Society of Cardiology, Arman
Postadzhiyan; Cyprus: Cyprus Society of Cardiology, Georgios P.
Georghiou; Czech Republic: Czech Society of Cardiology, Zuzana
Motovska; Denmark: Danish Society of Cardiology, Erik Lerkevang
Grove; Estonia: Estonian Society of Cardiology, Toomas Marandi;
Finland: Finnish Cardiac Society, Tuomas Kiviniemi; The Former
Yugoslav Republic of Macedonia: Macedonian Society of
Cardiology, Sasko Kedev; France: French Society of Cardiology,
Martine Gilard; Germany: German Cardiac Society, Steffen
Massberg; Greece: Hellenic Society of Cardiology, Dimitrios
Alexopoulos; Hungary: Hungarian Society of Cardiology, Robert
Gabor Kiss; Iceland: Icelandic Society of Cardiology, Ingibjorg Jona
Gudmundsdottir; Ireland: Irish Cardiac Society, Eugène P.
McFadden; Israel: Israel Heart Society, Eli Lev; Italy: Italian
Federation of Cardiology, Leonardo De Luca; Kazakhstan:
Association of Cardiologists of Kazakhstan, Akhmetzhan Sugraliyev;
Kosovo: Kosovo Society of Cardiology, Edmond Haliti;
Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov,
Latvia: Latvian Society of Cardiology, Gustavs Latkovskis;
What is new in the 2017 ESC focussed update on DAPT?
New/revised concepts
Metallic stent and DAPT duraon
Switch between P2Y12 inhibitors
Risk scores to guide DAPT duraon
−PRECISE DAPT score
−DAPT score
Specific profiling
−Definion of complex PCI
−Unfavourable profile for OAC and APT
−Gender consideraons and 
special populaons
DAPT duraon without stenng
−Medical management
−CABG or cardiac surgery
Ancoagulaon and DAPT
−Acute and chronic seng
−Dosing regimen
Pretreatment with P2Y12 inhibitors 
when PCI is planned
Liberal use of PPI to migate GI bleeding 
risk
Ticagrelor interrupon of 3 days prior 
elecve surgery
Roune platelet funcon tesng to adjust 
therapy
Dual therapy as an alternave to triple 
therapy when bleeding risk outweighs the 
ischaemic risk 
Change in recommendaons
Disconnuaon of P2Y12 inhibitor therapy 
aer 6 months when stenng ACS paents 
with PRECISE-DAPT ≥ 25
New recommendaons 2017
I
7102erofeB
Disconnuaon of anplatelet treatment 
in paents treated with OAC should be 
considered at 12 months. 
The occurrence of aconable bleeding while 
on DAPT should prompt reconsideraon of 
type and duraon of DAPT regimen. 
The decision for DAPT duraon should be 
dynamic and reassessed during the course 
of the inially selected DAPT regimen. 
IIB
6-month DAPT regimen In paents with 
SCAD treated with drug-coated balloon 
Ticagrelor 60 mg b.i.d preferred over other 
oral P2Y
12
 inhibitors for DAPT connuaon 
>12 months in post-MI 
IIIIIA
Early administraon of cagrelor/ clopidogrel 
in NSTE-ACS with invasive approach
Elecve surgery requiring disconnuaon 
of the P2Y
12
 inhibitor aer 1 month
ACS ¼ acute coronary syndrome; APT ¼ anti-platelet therapy; CABG ¼ coronary artery bypass graft; DAPT ¼ dual antipla-
telet therapy; MI ¼ myocardial infarction; NSTE¼ Non-st-segment elevation; OAC ¼ oral anti-coagulant;PCI ¼ percuatenous
coronary intervention; PRECISE-DAPT ¼ PREdicting bleeding Complications In patients undergoing Stent implantation and
subsEquent Dual Anti Platelet Therapy; Stable CAD ¼ stable coronary artery disease.
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Lithuania: Lithuanian Society of Cardiology, Birute Petrauskiene;
Luxembourg: Luxembourg Society of Cardiology, Steve Huijnen;
Malta: Maltese Cardiac Society, Caroline Jane Magri; Morocco:
Moroccan Society of Cardiology, Rhizlan Cherradi; The
Netherlands: Netherlands Society of Cardiology, Jurrien M Ten
Berg; Norway: Norwegian Society of Cardiology, Jan Eritsland;
Poland: Polish Cardiac Society, Andrzej Budaj; Portugal:
Portuguese Society of Cardiology, Carlos Tavares Aguiar; Russian
Federation: Russian Society of Cardiology, Dmitry Duplyakov; San
Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia:
Cardiology Society of Serbia, Nebojsa M. Antonijevic; Slovakia:
Slovak Society of Cardiology, Zuzana Motovska; Slovenia: Slovenian
Society of Cardiology, Zlatko Fras; Spain: Spanish Society of
Cardiology, Antonio Tello Montoliu; Sweden: Swedish Society
of Cardiology, Christoph Varenhorst; Switzerland: Swiss Society of
Cardiology, Dimitri Tsakiris; Tunisia: Tunisian Society of Cardiology
and Cardio-Vascular Surgery, Faouzi Addad; Turkey: Turkish
Society of Cardiology, Sinan Aydogdu; Ukraine: Ukrainian
Association of Cardiology, Alexander Parkhomenko; United
Kingdom: British Cardiovascular Society, Tim Kinnaird.
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